<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='/w/ProjectMundo-Anon-106A/style/jats-html.xsl'?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-52388-1
   </article-id>
   <article-id pub-id-type="manuscript">
    52388
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-52388-1
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/308/575
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4028/67/1990/283/1897
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4028/67/1059/2325
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/250/1619/382
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /42/109
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /38/5
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /64/60
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/44
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/31
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /14
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Uhariri wa CRISPR/Cas9 wa NKG2A unaboresha ufanisi wa seli asili za muuaji zenye kipokezi cha kingamwili chenye mwelekeo wa CD33
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0009-0009-2392-6416
     </contrib-id>
     <name name-style="western">
      <surname>
       Bexte
      </surname>
      <given-names>
       Tobias
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <name name-style="western">
      <surname>
       Albinger
      </surname>
      <given-names>
       Nawid
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Al Ajami
      </surname>
      <given-names>
       Ahmad
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-5844-1587
     </contrib-id>
     <name name-style="western">
      <surname>
       Wendel
      </surname>
      <given-names>
       Philipp
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff9">
      9
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Buchinger
      </surname>
      <given-names>
       Leon
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Gessner
      </surname>
      <given-names>
       Alec
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-4284-2006
     </contrib-id>
     <name name-style="western">
      <surname>
       Alzubi
      </surname>
      <given-names>
       Jamal
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-9565-2850
     </contrib-id>
     <name name-style="western">
      <surname>
       Särchen
      </surname>
      <given-names>
       Vinzenz
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-2650-586X
     </contrib-id>
     <name name-style="western">
      <surname>
       Vogler
      </surname>
      <given-names>
       Meike
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1010-296X
     </contrib-id>
     <name name-style="western">
      <surname>
       Rasheed
      </surname>
      <given-names>
       Hadeer Mohamed
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="aff" rid="Aff15">
      15
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <name name-style="western">
      <surname>
       Jung
      </surname>
      <given-names>
       Beate Anahita
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au12">
     <name name-style="western">
      <surname>
       Wolf
      </surname>
      <given-names>
       Sebastian
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au13">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-0865-9582
     </contrib-id>
     <name name-style="western">
      <surname>
       Bhayadia
      </surname>
      <given-names>
       Raj
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au14">
     <name name-style="western">
      <surname>
       Oellerich
      </surname>
      <given-names>
       Thomas
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au15">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-1070-0727
     </contrib-id>
     <name name-style="western">
      <surname>
       Klusmann
      </surname>
      <given-names>
       Jan-Henning
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au16">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-4876-802X
     </contrib-id>
     <name name-style="western">
      <surname>
       Penack
      </surname>
      <given-names>
       Olaf
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="aff" rid="Aff16">
      16
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au17">
     <name name-style="western">
      <surname>
       Möker
      </surname>
      <given-names>
       Nina
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff17">
      17
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au18">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-7757-4630
     </contrib-id>
     <name name-style="western">
      <surname>
       Cathomen
      </surname>
      <given-names>
       Toni
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
     <xref ref-type="aff" rid="Aff18">
      18
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au19">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4158-5872
     </contrib-id>
     <name name-style="western">
      <surname>
       Rieger
      </surname>
      <given-names>
       Michael A.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
     <xref ref-type="aff" rid="Aff19">
      19
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au20">
     <name name-style="western">
      <surname>
       Imkeller
      </surname>
      <given-names>
       Katharina
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au21">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-8530-1192
     </contrib-id>
     <name name-style="western">
      <surname>
       Ullrich
      </surname>
      <given-names>
       Evelyn
      </given-names>
     </name>
     <address>
      <email>
       evelyn@ullrichlab.de
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="corresp" rid="IDs41467024523881_cor21">
      x
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, Department of Pediatrics
      </institution>
      <institution content-type="org-name">
       Experimental Immunology and Cell Therapy
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Department of Pediatrics
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.511198.5
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Frankfurt Cancer Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/02y3dtg29
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.433743.4
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 1093 4868
      </institution-id>
      <institution content-type="org-division">
       German Red Cross Blood Service Baden-Württemberg – Hessen
      </institution>
      <institution content-type="org-name">
       Institute for Transfusion Medicine and Immunohematology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       University Cancer Center (UCT)
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, University Hospital
      </institution>
      <institution content-type="org-name">
       Neurological Institute / Edinger Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/05n911h24
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.6546.1
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 0940 1669
      </institution-id>
      <institution content-type="org-division">
       Institute for Organic Chemistry and Biochemistry
      </institution>
      <institution content-type="org-name">
       Technical University of Darmstadt
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Darmstadt
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Frankfurt/Mainz
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff9">
     <label>
      9
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cdgtt98
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Research Center (DKFZ)
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Heidelberg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff10">
     <label>
      10
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt, University Hospital
      </institution>
      <institution content-type="org-name">
       Department of Medicine II - Hematology and Oncology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff11">
     <label>
      11
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/0245cg223
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5963.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0491 7203
      </institution-id>
      <institution content-type="org-division">
       Institute for Transfusion Medicine and Gene Therapy
      </institution>
      <institution content-type="org-name">
       Medical Center – University of Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff12">
     <label>
      12
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/0245cg223
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5963.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0491 7203
      </institution-id>
      <institution content-type="org-division">
       Center for Chronic Immunodeficiency
      </institution>
      <institution content-type="org-name">
       Faculty of Medicine, University of Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff13">
     <label>
      13
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04cvxnb49
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7839.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 9721
      </institution-id>
      <institution content-type="org-division">
       Goethe University Frankfurt
      </institution>
      <institution content-type="org-name">
       Institute for Experimental Pediatric Hematology and Oncology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff14">
     <label>
      14
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/001w7jn25
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.6363.0
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2218 4662
      </institution-id>
      <institution content-type="org-division">
       Charité, University Berlin and Humboldt-University Berlin, Department of Hematology
      </institution>
      <institution content-type="org-name">
       Oncology and Tumor Immunology
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Berlin
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff15">
     <label>
      15
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00mzz1w90
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7155.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2260 6941
      </institution-id>
      <institution content-type="org-division">
       Clinical Pathology Department, Faculty of Medicine
      </institution>
      <institution content-type="org-name">
       Alexandria University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Alexandria
     </addr-line>
     <country country="EG">
      Egypt
     </country>
    </aff>
    <aff id="Aff16">
     <label>
      16
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Berlin
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Berlin
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff17">
     <label>
      17
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.59409.31
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0552 5033
      </institution-id>
      <institution content-type="org-name">
       Miltenyi Biotec B.V. &amp; Co. KG
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Bergisch Gladbach
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff18">
     <label>
      18
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.7497.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0492 0584
      </institution-id>
      <institution content-type="org-name">
       German Cancer Consortium (DKTK) partner site Freiburg
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Freiburg
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
    <aff id="Aff19">
     <label>
      19
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04ckbty56
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.511808.5
      </institution-id>
      <institution content-type="org-name">
       Cardio-Pulmonary-Institute
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Frankfurt am Main
     </addr-line>
     <country country="DE">
      Germany
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Tobias Bexte, Nawid Albinger.
     </p>
    </fn>
    <corresp id="IDs41467024523881_cor21">
     <label>
      x
     </label>
     <email>
      evelyn@ullrichlab.de
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     30
    </day>
    <month>
     9
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="8439">
    1
   </issue>
   <elocation-id>
    8439
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      5
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      17
     </day>
     <month>
      1
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      30
     </day>
     <month>
      8
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      30
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Muhtasari
    </title>
    <p id="Par1">
     Seli asili za muuaji (NK) zilizobadilishwa na kipokezi cha kingamwili chenye mchanganyiko (CAR) zinaonyesha shughuli ya kupambana na leukemia ya myeloid kali (AML) in vivo. Hata hivyo, uwezo wa seli za NK kuua uvimbe mara nyingi hudhoofishwa na mwingiliano kati ya antijeni ya leukositi ya binadamu (HLA)-E na kipokezi cha kuzuia, NKG2A. Hapa, tunaelezea mkakati unaoshinda uzuiaji wa seli za CAR-NK unaosababishwa na kizuizi cha kinga cha HLA-E-NKG2A. Tunazalisha seli za CAR-NK maalum kwa CD33, zinazolenga AML (CAR33) pamoja na usumbufu wa jeni unaotegemea CRISPR/Cas9 wa jeni la
     <italic>
      KLRC1
     </italic>
     linaloandika NKG2A. Kwa kutumia uchambuzi wa multi-omics wa seli moja, tulibaini sifa za usambazaji wa uanzishaji na ukomavu katika seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK, ambazo zinahifadhiwa baada ya kuathiriwa na seli za AML. Zaidi ya hayo, seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK zinaonyesha uwezo mkubwa wa kuua seli za AML na milipuko ya msingi in vitro na in vivo. Kwa hivyo tunahitimisha kuwa seli za CAR-NK zisizo na NKG2A zina uwezo wa kupita ukandamizaji wa kinga katika AML.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     NK cell-based therapy can kill acute myeloid leukemia (AML), but immune suppression may occur. Here the authors overcome the immunosuppression of AML-targeted CAR33-NK cells via non-viral CRISPR-editing of the immune checkpoint NKG2A, leading to an enhanced potency of the CAR-NK cell product with sustained anti-tumor efficacy.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1107">
      Immunology
     </kwd>
    </nested-kwd>
   </kwd-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      8439
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      9
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      5
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_52388.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Utangulizi
   </title>
   <p id="Par3">
    Utafiti juu ya tiba mpya za seli za chimeric antigen receptor (CAR)-T umepelekea kuidhinishwa kwa bidhaa kadhaa kwa ajili ya matibabu ya magonjwa yanayotokana na seli za B
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     ,
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Mbali na tiba za seli za CAR-T zilizoidhinishwa na Mamlaka ya Chakula na Dawa ya Marekani na Shirika la Dawa la Ulaya, seli za CAR zinazolenga CD19 za asili za kuua (NK) ziliripotiwa kuwa salama na kuwa na ufanisi sawa na seli za CAR-T katika jaribio la kliniki
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    . Uundaji wa bidhaa za CAR kwa ajili ya matibabu ya leukemia ya myeloid kali (AML) ni changamoto zaidi kutokana na utofauti wa ugonjwa na ukosefu wa antijeni za kipekee za AML
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Hata hivyo, antijeni moja yenye matumaini kwa tiba ya seli inayotegemea CAR ni CD33, ambayo inaonyeshwa kwenye milipuko ya leukemiki na seli zinazozalisha leukemia kwa hadi 88% ya wagonjwa wa AML, na matokeo ya awali ya majaribio yameonyesha shughuli ya kupambana na AML ya seli za CAR-T maalum za CD33
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
    </sup>
    . Njia mbadala yenye matumaini kwa tiba ya seli za CAR-T ni seli za NK zilizohamishwa kwa kupandikiza, ambazo zina muda mfupi wa maisha kuliko seli za T, zinahusishwa na athari chache za pembeni, na zina uwezo wa kuua bila kutegemea CAR, ambayo imeonyeshwa katika muktadha wa AML inayotoa ligandi ya NKG2D
    <sup>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
    </sup>
    .
   </p>
   <p id="Par4">
    Katika kazi za awali za majaribio, tulizalisha seli za msingi za CAR (CAR33)-NK zinazolenga CD33 ambazo zilionyesha kuongezeka kwa shughuli za kupambana na leukemia dhidi ya seli za AML za CD33 katika mfano wa xenograft in vivo
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    . Hata hivyo, ufanisi wa seli za CAR33-NK unaweza kuwa na mipaka kutokana na kuongezeka kwa vizuizi vya kinga katika mazingira ya uvimbe yanayozuia kinga. Kwa kweli, uanzishaji wa seli za NK unadhibitiwa kwa ukaribu na usawa wa ishara za kuanzisha na kuzuia zinazosimamiwa na orodha ya vipokezi tofauti vinavyoonyeshwa kwenye uso wa seli. Miongoni mwa hivi, kipokezi kimoja muhimu cha kuzuia ni kundi la NK 2A (NKG2A) ambalo linaandikwa na jeni la
    <italic>
     KLRC1
    </italic>
    . Linaunganisha na protini ya MHC I isiyo ya kawaida HLA-E, ambayo mara nyingi huonyeshwa zaidi kwenye seli za uvimbe
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Sisi na wengine tumeonyesha kwamba kuvuruga mhimili wa NKG2A-HLA-E kwa kutumia kingamwili zinazozuia NKG2A, kama vile monalizumab au kuvuruga kwa CRISPR/Cas9 kwa
    <italic>
     KLRC1
    </italic>
    katika seli za NK, kunaweza kuongeza kwa kiasi kikubwa uwezo wa sumu wa seli za NK dhidi ya myeloma nyingi
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Tuliendelea kuona kwamba mistari mbalimbali ya seli za AML, na pia milipuko ya msingi ya AML inaonyesha viwango vya juu vya HLA-E, na kwamba usemi wa HLA-E unaboreshwa kufuatia kuathiriwa na IFN-γ, sitokini inayojulikana kuwa inatolewa kwa wingi na seli za CAR-NK kufuatia kuwasiliana na seli lengwa. Kwa hiyo tulidhani kwamba mhimili wa NKG2A-HLA-E unaweza kuwa na jukumu muhimu katika uchovu wa seli za CAR-NK na kwamba kuondoa jeni la NKG2A linaloandika
    <italic>
     KLRC1
    </italic>
    katika CAR-NK zinazolenga CD33 kutaboresha shughuli zao za kuua AML
    <sup>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    .
   </p>
   <p id="Par5">
    Katika kazi hii, tunaelezea uzalishaji wa seli za NK zilizobadilishwa mara mbili kwa kuchanganya upitishaji wa lentiviral CAR33 na kuvuruga kwa jeni la
    <italic>
     KLRC1
    </italic>
    kwa CRISPR/Cas9. Seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zilizotokana zilionyesha uwezo wa sumu ulioongezeka kwa kiasi kikubwa ikilinganishwa na seli za CAR33-NK au
    <italic>
     KLRC1
    </italic>
    -NK dhidi ya mstari wa seli za CD33/HLA-E OCI-AML2 na kundi la seli za milipuko ya msingi zilizotokana na wagonjwa
    <sup/>
    .
   </p>
   <p id="Par6">
    Vipimo vya transcriptome ya seli moja na epitope vilionyesha mifumo ya usemi wa jeni inayosababisha uanzishaji, ukomavu na usumamizi wa sumu katika seli za CAR33-NK na seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zilizobadilishwa mara mbili, kulingana na uwezo wa kuua ulioongezeka. Inashangaza, seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zilionyesha kuongezeka kwa utoaji wa IFN-γ ikilinganishwa na seli za
    <italic>
     KLRC1
    </italic>
    -NK na CAR33-NK zilizobadilishwa mara moja, ambayo ilidumishwa kufuatia kuwasiliana na seli lengwa
    <sup/>
    .
   </p>
   <p id="Par7">
    Matokeo yetu yanaangazia uwezo wa kliniki wa kubadilisha muundo wa vipokezi vya uso wa seli za NK kwa kuchanganya uhandisi wa CAR-NK na uhariri wa jeni ili kuondoa vipokezi vya kuzuia
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
    </sup>
    . Marekebisho ya hali ya juu yanafungua safu ya uwezekano na yanapaswa kuzingatiwa wakati wa kubuni tiba za msingi wa seli za kinga ili kulenga magonjwa yenye mahitaji ya matibabu yasiyotimizwa.
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec3">
    <title>
     Seliseli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK zilizobadilishwa kijenetiki mara mbili zinachanganya kuingiza CAR na kupunguza usemi wa NKG2A
    </title>
    <p id="Par8">
     CAR33-NK cells zilitengenezwa kwa kutumia transduction ya lentivirus ya seli za msingi za NK zilizotengwa kutoka kwa damu ya pembeni (PB) ya wafadhili wenye afya (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1a
     </xref>
     ) ili kuonyesha CAR ya kizazi cha pili inayolenga CD33 kama inavyoonyeshwa kwenye Fig.
     <xref ref-type="fig" rid="Fig1">
      1a
     </xref>
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     . Kufuatia utaratibu wa transduction, usemi wa CAR ulifikiwa katika 30-70% ya seli za NK (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b, c
     </xref>
     ). Kwa ajili ya NKG2A-knockout, seli za NK zisizo na transduction (NT) na CAR33-NK zilifanyiwa nucleofection na CRISPR/Cas9 ribonucleoprotein (RNP) complex inayolenga eneo la
     <italic>
      KLRC1
     </italic>
     . Uhamisho wa RNP usio wa virusi ulisababisha kupungua kwa kiasi kikubwa kwa seli chanya za NKG2A kwa ~50% ikilinganishwa na seli za NT-NK (~90% NKG2A) (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b, d
     </xref>
     ). Ufanisi wa kuvuruga jeni la
     <italic>
      KLRC1
     </italic>
     ulithibitishwa kwa seli za NK zilizohaririwa kwa uwepo au kutokuwepo kwa CAR, kwa kutumia genotyping kwa T7 endonuclease 1 (T7E1; &gt;67%) na upimaji wa kuingiza/kufuta (indels) kwa Inference of CRISPR Edits (ICE; &gt;90%) (Fig.
     <xref ref-type="fig" rid="Fig1">
      1e, f
     </xref>
     ; Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1b
     </xref>
     <sup/>
     . Umaalumu wa CRISPR/Cas9 nuclease inayolenga
     <italic>
      KLRC1
     </italic>
     katika seli za NK umeonyeshwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Uchambuzi wa usambazaji wa indel ulionyesha kuingizwa kwa +1 kwa kiasi kikubwa ikifuatiwa na kufutwa kwa −15 katika wafadhili watatu tofauti kwa uwepo au kutokuwepo kwa CAR. Kufutwa kwa −15 kunaweza kuelezewa na uwepo wa mfuatano wa micro-homology unaozunguka eneo la kukata (Fig.
     <xref ref-type="fig" rid="Fig1">
      1f
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1c
     </xref>
     ,
     <xref ref-type="supplementary-material" rid="MOESM1">
      1d
     </xref>
     ). Ukuaji uliongezeka sawa katika hali zote nne kwa muda (seli za NT-NK,
     <italic>
      KLRC1
     </italic>
     -NK, CAR33-NK na CAR33-CAR-
     <italic>
      KLRC1
     </italic>
     -NK; iliyoonyeshwa katika kiwango cha upanuzi wa log-fold, Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ). Hata hivyo, tuliona kupungua kwa muda kwa idadi ya seli kufuatia nucleofection inayotegemea mapigo ya umeme ili kuzalisha RNP-based gene knockout (Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     ). Kupungua kwa idadi ya seli kulihusiana moja kwa moja na utaratibu wa nucleofection siku ya 9 (tarehe ya kizazi cha CRISPR/Cas9
     <italic>
      KLRC1
     </italic>
     -KO), lakini maandalizi yote ya seli yalipona na kuonyesha viwango vya ukuaji sawa kuanzia siku ya 13 na kuendelea (Fig.
     <xref ref-type="fig" rid="Fig1">
      1g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S2a–c
     </xref>
     ). Nucleofection na sgRNAs zisizohusiana au nucleofection ya MOCK tupu ilisababisha kiwango sawa cha ukuaji wa seli za NK ikilinganishwa na sgRNA inayolenga
     <italic>
      KLRC1
     </italic>
     katika maandalizi ya seli za CAR33-NK na NT-NK (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S2b, c
     </xref>
     ). Muhimu, CRISPR/Cas9-editing ya
     <italic>
      KLRC1
     </italic>
     katika seli za CAR33-NK ilionyesha uhariri wa jeni wenye ufanisi ambao ulisababisha kupungua kwa nguvu kwa usemi wa uso wa seli za NKG2A (Fig.
     <xref ref-type="fig" rid="Fig1">
      1b
     </xref>
     )
     <sup/>
     .
     <fig id="Fig1" position="float">
      <label>
       Fig. 1
      </label>
      <caption xml:lang="en">
       <title>
        Mchakato wa kizazi na tathmini ya CRISPR/Cas9 knockout kwa seli za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mpango wa kizazi cha ndani ya vitro cha seli za msingi za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK.
        <bold>
         b
        </bold>
        Mchoro wa mfano wa flow cytometry wa usemi wa CAR33 na NKG2A kwenye seli za NK zilizobadilishwa.
        <bold>
         c
        </bold>
        Uchambuzi wa usemi wa uso wa CAR33 kwa kutumia flow cytometry kwa muda (
        <italic>
         n
        </italic>
        = 6–9). Wastani ± SD. CAR33 dhidi ya CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        : d14 (
        <italic>
         n
        </italic>
        = 0.1158), d21 (
        <italic>
         n
        </italic>
        = 0.1296), d28 (
        <italic>
         n
        </italic>
        = 0.8095).
        <bold>
         d
        </bold>
        Uchambuzi wa flow cytometry wa usemi wa NKG2A kufuatia CRISPR/Cas9 knockout ya jeni la
        <italic>
         KLRC1
        </italic>
        (
        <italic>
         n
        </italic>
        = 7). Wastani ± SD.
        <bold>
         e
        </bold>
        Mara kwa mara ya usumbufu wa
        <italic>
         KLRC1
        </italic>
        kwenye kiwango cha jeni ilitathminiwa kwa kutumia Inference of CRISPR Edits (ICE) na T7E1 assay kwa seli za CAR zilizopitishwa (+CAR) na seli za NK za udhibiti (−CAR) (
        <italic>
         n
        </italic>
        = 3). Wastani ± SD.
        <bold>
         f
        </bold>
        Profaili za usambazaji wa kuingiza/kufuta (indel) zilionyeshwa kwa uchambuzi wa ICE kutoka kwa wafadhili watatu tofauti (D1, D2, D3).
        <bold>
         g
        </bold>
        Upanuzi na mtiririko wa kazi wa kizazi cha seli za NK zisizopitishwa (NT)-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK katika uwepo wa IL-2 (500 U/mL) na IL-15 (10 ng/ml Miltenyi Biotec au 50 ng/mL CellGenix) (
        <italic>
         n
        </italic>
        = 7). Wastani ± SD (ns = 0.9991). Uchambuzi wa takwimu ulifanywa kwa kutumia ANOVA ya njia mbili (
        <bold>
         c
        </bold>
        ,
        <bold>
         g
        </bold>
        ) na mtihani wa mwanafunzi wa paired
        <italic>
         t
        </italic>
        (
        <bold>
         d
        </bold>
        ,
        <bold>
         e
        </bold>
        ). Kiwango cha
        <italic>
         n
        </italic>
        ni marudio ya kibiolojia (kutoka kwa wafadhili tofauti wa afya) (
        <bold>
         c
        </bold>
        –
        <bold>
         e
        </bold>
        ,
        <bold>
         g
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Uchambuzi wa Multi-omics unaonyesha hali ya seli iliyoamilishwa ya seli za CAR33-(
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     )-NK
    </title>
    <p id="Par9">
     Ili kuchunguza athari zinazotokana na usemi wa CAR33 na/au
     <italic>
      KLRC1
     </italic>
     knockout katika seli za NK, tuliamua usemi wa jeni na alama za uso katika kiwango cha seli moja kwa kutumia amplicon-based cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq). Kwa hiyo, mabwawa manne ya seli za NK (NT,
     <italic>
      KLRC1
     </italic>
     , CAR33 na CAR33-
     <italic>
      KLRC1
     </italic>
     ) kutoka kwa wafadhili wawili tofauti yalichaguliwa kwa kutumia flow cytometry (Fig.
     <xref ref-type="fig" rid="Fig2">
      2a
     </xref>
     ) ili kupata karibu 100% ya usemi wa CAR safi (kwa CAR33 na CAR33-
     <italic>
      KLRC1
     </italic>
     ) na/au NKG2A-hasi (kwa
     <italic>
      KLRC1
     </italic>
     na CAR33-
     <italic>
      KLRC1
     </italic>
     ) idadi ya seli za NK. Baada ya udhibiti wa ubora na uchujaji wa data za CITE-seq, jumla ya seli 32,908 na 20,197 kutoka kwa wafadhili D1 na D2, mtawalia, zilichambuliwa katika mtiririko wa kazi wa pamoja wa kompyuta. Tulitumia mfano wa takwimu uliotumika kwa data za seli moja zilizojumuishwa za pseudo-bulk ili kugundua mabadiliko ya jumla katika usemi yanayosababishwa na marekebisho ya jeni moja au mbili. Mfano wetu wa takwimu ulikuwa na vigezo vinne na ulitathmini kwa wakati mmoja utofauti wa kati ya wafadhili, athari ya CAR (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     ), athari ya
     <italic>
      KLRC1
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig2">
      2c
     </xref>
     ) pamoja na athari ya ushirikiano wa marekebisho mawili (CAR:
     <italic>
      KLRC1
     </italic>
     , Fig.
     <xref ref-type="fig" rid="Fig2">
      2d
     </xref>
     ). Kumbuka, mabadiliko ambayo mfano unahesabu kwa ushirikiano wa CAR:
     <italic>
      KLRC1
     </italic>
     ni mabadiliko yanayoonekana katika seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ambayo hayawezi kuelezewa na mchanganyiko rahisi wa CAR na
     <italic>
      KLRC1
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig2">
      2d
     </xref>
     ). Mabadiliko makubwa zaidi katika usemi wa jeni na protini yalionekana baada ya kuanzishwa kwa CAR inayolenga CD33 katika seli za NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Seli za CAR33 zilizopitishwa zilionyesha viwango vya juu vya jeni zinazokodisha protini za MHC darasa la II, kama
     <italic>
      HLA-DQA1, HLA-DQB1
     </italic>
     ,
     <italic>
      HLA-DRA, HLA-DPB1
     </italic>
     , na HLA darasa la II histocompatibility antigen gamma chain (
     <italic>
      CD74
     </italic>
     ) ikilinganishwa na seli za NK zisizo na transduction (NT) (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Usemi wa jeni hizi kawaida huonekana katika seli za T zilizoamilishwa, na kuongezeka kwao katika majaribio yetu kunaweza kuhusishwa na uanzishaji wa njia za ishara za chini za TCR au CAR
     <sup>
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
     </sup>
     . Seli za CAR33 zilizopitishwa pia zilionyesha viwango vya juu vya unakili wa jeni za alama za kukomaa na kuamsha kama FcγRIIIa/CD16, CD70, integrin alpha M (CD11b), na interleukin-2 receptor alpha chain (IL2Rα/CD25), pamoja na alama za uhamaji kama C-C chemokine receptor type 2 (
     <italic>
      CCR2
     </italic>
     ) na C-X-C chemokine receptor type 4 (
     <italic>
      CXCR4
     </italic>
     ) (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Jeni zinazokodisha protini zinazotolewa kwenye seli zisizo komaa au zilizozuiliwa kama Zinc Finger Protein 683 (
     <italic>
      ZNF683
     </italic>
     ) zilipunguzwa baada ya kuanzishwa kwa CAR33 ikilinganishwa na maandalizi ya seli za NT-NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     . Inashangaza,
     <italic>
      KLRC1
     </italic>
     knockout katika seli za NK ilisababisha mabadiliko madogo tu katika mifumo ya usemi wa jeni na protini na kuongezeka kwa wastani kwa FcγRIIIa/CD16 na kupungua kwa
     <italic>
      ZNF683
     </italic>
     ikilinganishwa na seli za NT-NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2c
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Mwisho, mchanganyiko wa usemi wa CAR33 na
     <italic>
      KLRC1
     </italic>
     knockout haukusababisha mabadiliko yoyote ya ziada katika usemi wa jeni na alama za uso ikilinganishwa na seli za NK zilizobadilishwa moja (CAR33 au
     <italic>
      KLRC1
     </italic>
     ) (Fig.
     <xref ref-type="fig" rid="Fig2">
      2d
     </xref>
     ). Njia yetu ya kompyuta iligundua mwingiliano kati ya usemi wa CAR33 na
     <italic>
      KLRC1
     </italic>
     , unaosababisha kuongezeka kwa
     <italic>
      ZNF683
     </italic>
     na chemokine (C-C motif) ligand 1 (
     <italic>
      CCL1
     </italic>
     ), na kupungua kwa
     <italic>
      CCR2
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig2">
      2d
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3a
     </xref>
     ). Hii, hata hivyo, inaweza kuelezewa na ukweli kwamba mabadiliko yanayosababishwa na CAR33 na
     <italic>
      KLRC1
     </italic>
     hayaongezeki katika marekebisho ya jeni mbili: Kwa mfano, marekebisho yote mawili ya jeni husababisha kupungua kwa
     <italic>
      ZNF683
     </italic>
     , wakati mchanganyiko wa marekebisho yote mawili haupunguzi zaidi usemi wa
     <italic>
      ZNF683
     </italic>
     . Katika kiwango cha protini, uchambuzi wa usemi wa protini kwa Ab-seq na uchambuzi wa mtiririko wa seli za NK zilizobadilishwa kijenetiki haukuonyesha mabadiliko ya alama za kawaida za seli za NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e, f
     </xref>
     ). Kuongezeka kwa wastani kwa CD16 kulithibitishwa katika Ab-seq na uchambuzi wa mtiririko pamoja na tabia ya mara kwa mara ya vipokezi vya seli za NK kama CD56, DNAM1 (CD314), NKG2D (CD226), CD57, NKp44, NKp30 (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e, f
     </xref>
     ). Pia, hakuna tofauti zilizoonekana kwa usemi wa CD69, TIGIT au TIM-3 kati ya maandalizi manne ya seli za NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e, f
     </xref>
     )
     <sup/>
     .
     <fig id="Fig2" position="float">
      <label>
       Fig. 2
      </label>
      <caption xml:lang="en">
       <title>
        Usemi wa CAR33 na
        <italic>
         KLRC1
        </italic>
        knockout husababisha mabadiliko katika jeni za seli za NK lakini si katika profaili za usemi wa alama za uso.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mpango wa mkakati wa kupanga kwa uchambuzi wa seli moja ya NK wa maandalizi manne tofauti ya seli za NK. Seli za CAR-NK ziliwekwa kwenye CAR+,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK seli kwenye NKG2A- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK seli kwenye CD33+/NKG2A− seli za NK kabla ya uchambuzi wa CITE-Seq.
        <bold>
         b
        </bold>
        -
        <bold>
         d
        </bold>
        Mabadiliko ya jumla ya usambazaji wa jeni (RNA) katika seli za NK baada ya kuanzishwa kwa CAR33 (
        <bold>
         b
        </bold>
        ), knockout ya
        <italic>
         KLRC1
        </italic>
        (
        <bold>
         c
        </bold>
        ) na athari za ushirikiano wa CAR33 na knockout ya
        <italic>
         KLRC1
        </italic>
        (
        <bold>
         d
        </bold>
        ). Mtihani wa takwimu: mtihani wa quasi-likelihood (QL) F dhidi ya kizingiti (
        <bold>
         b
        </bold>
        –
        <bold>
         d
        </bold>
        ). Mchoro wa volcano unaonyesha uchambuzi wa pamoja wa seli za NK kutoka kwa wafadhili D1 na D2 na kuonyesha thamani ya
        <italic>
         p
        </italic>
        iliyorekebishwa (
        <italic>
         y
        </italic>
        -axis) na logFC iliyodhaniwa (
        <italic>
         x
        </italic>
        -axis) kwa kila kipengele cha jeni na kwa kila mabadiliko ya kijenetiki (CAR33 (
        <bold>
         b
        </bold>
        ), KLRC1
        <sup>
         ko
        </sup>
        (
        <bold>
         c
        </bold>
        ), athari ya ushirikiano wa CAR33 na
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        (
        <bold>
         d
        </bold>
        )). Vipengele vilivyopandishwa na kushushwa vimeangaziwa kwa rangi. Mstari wa usawa unaonyesha FDR ya 5% na mistari ya wima inabainisha kiwango cha logFC kati ya −log2 (1.2) na log2 (1.2). Jeni zilizochaguliwa za maslahi zimewekwa alama. Mtihani wa takwimu: mtihani wa quasi-likelihood (QL) F dhidi ya kizingiti.
        <bold>
         e
        </bold>
        Usambazaji wa usemi wa alama za uso kutoka kwa data ya CITE-seq kwa maandalizi manne ya seli. Usambazaji umeonyeshwa kama wingi, na eneo chini ya mlingano limewekwa sawa na 1.
        <bold>
         f
        </bold>
        Usemi wa uso wa vipokezi tofauti vya seli za NK ulipimwa kwa kutumia flow cytometry. Histograms za uwakilishi zinaonyeshwa.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par10">
     Tulichambua profaili za usemi wa RNA na protini kwa pamoja katika kiwango cha seli moja ili kuchunguza kama mabadiliko ya jumla ya usemi yaliyoonekana yalihusishwa na vikundi maalum vya seli (Fig.
     <xref ref-type="fig" rid="Fig3">
      3
     </xref>
     ). Zote, usemi wa RNA na protini katika kiwango cha seli moja ulithibitisha tabia safi ya seli za NK na kutokuwepo kwa alama za seli za T (angalia Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3b, c
     </xref>
     ). Inashangaza, muundo wa bwawa la seli za
     <italic>
      KLRC1
     </italic>
     -NK ulifanana na ule wa bwawa la NT-NK na muundo wa bwawa la CAR33-NK ulikuwa zaidi kulinganishwa na ule wa bwawa la seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK (Fig.
     <xref ref-type="fig" rid="Fig3">
      3a–c
     </xref>
     ). Uchambuzi wa pamoja wa vikundi vidogo vya profaili za usemi wa seli za NK kutoka kwa maandalizi yote manne ya seli ulitambua makundi sita ya seli zenye hali tofauti za unakili (Fig.
     <xref ref-type="fig" rid="Fig3">
      3c–e
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d
     </xref>
     ). Ili kuelezea kwa ufanisi hali tofauti za unakili, tuligawanya vipengele vya jeni au protini vilivyochaguliwa kulingana na kazi zao katika “
     <italic>
      Checkpoint &amp; Suppressive Regulators
     </italic>
     ”, “
     <italic>
      Downstream TCR signaling
     </italic>
     ”, “
     <italic>
      Lymphocyte Activation
     </italic>
     ”, au “
     <italic>
      Mature NK Cells
     </italic>
     ” (Fig.
     <xref ref-type="fig" rid="Fig3">
      3f, g
     </xref>
     ). Maandalizi ya seli za NT-NK yalikuwa na seli nyingi kutoka kwa kundi la unakili 3, ambalo lilikuwa na sifa ya usemi wa jeni zinazohusiana na viwango vya chini vya uanzishaji na ukomavu wa seli za NK (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e–g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d
     </xref>
     ). Seli za
     <italic>
      KLRC1
     </italic>
     -NK zilionyesha uwiano mkubwa wa seli zinazohusiana na kundi la unakili 4, ambalo lilikuwa na jeni za seli za NK zinazohusiana na ukomavu (Fig.
     <xref ref-type="fig" rid="Fig2">
      2e–g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d
     </xref>
     ). Kinyume chake, profaili ya seli za CAR33-NK ilikuwa zaidi kuhusiana na makundi ya unakili 1, 2, na 6, ambapo seli zilikuwa na sifa za seli za NK zilizoamilishwa na kukomaa na ishara za chini za TCR, lakini pia za njia za kuzuia kinga (Fig.
     <xref ref-type="fig" rid="Fig3">
      3e–g
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S3d
     </xref>
     ). Kuhusu seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK, profaili ya unakili inaweza kuainishwa sawa na seli za CAR33-NK zinazohusiana na uanzishaji na ishara za chini za TCR (makundi 1, 2 na 6)
     <sup/>
     .
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="en">
       <title>
        CAR33- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK seli zina sehemu kubwa ya seli zilizo na fenotipu ya seli za NK zilizoamilishwa na kukomaa.
       </title>
       <p>
        <bold>
         a
        </bold>
        Uwakilishi wa t-SNE wa seli za NK katika kiwango cha seli moja kulingana na wasifu wao wa pamoja wa RNA na protini. Seli zimepangwa rangi na kugawanywa kulingana na hali tofauti (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK seli).
        <bold>
         b
        </bold>
        Uchambuzi wa sehemu kuu wa wasifu wa usemi wa seli za NK zilizobadilishwa tofauti kufuatia CITE-seq ya wafadhili wawili tofauti.
        <bold>
         c
        </bold>
        Ugawaji wa pamoja wa wasifu wa usemi wa seli za NK kutoka hali zote (uwakilishi wa t-SNE kama ilivyo katika (
        <bold>
         a
        </bold>
        )). Ugawaji wa Louvain kwenye matokeo ya PCA.
        <bold>
         d
        </bold>
        Wingi wa jamaa wa seli zinazohusiana na makundi sita kama asilimia ya seli zote zilizopangwa.
        <bold>
         e
        </bold>
        Wingi wa jamaa wa seli zinazohusiana na makundi madogo 6 kama sehemu ya mabwawa ya seli za NK. Kwa kila bwawa la seli za NK (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK), wingi wa jamaa juu ya makundi yote unajumlisha hadi moja.
        <bold>
         f
        </bold>
        Alama ya usemi tofauti wa sifa za jeni au protini zilizochaguliwa kwa kila kundi. Sifa za jeni na protini zimepangwa kulingana na kazi (Vikagua &amp; Vidhibiti vya Kukandamiza, Uashiriaji wa TCR wa Chini, Uamilishaji wa Lymphocyte, Seli za NK Zilizokomaa). Kila nukta inawakilisha jeni moja au sifa ya protini. Alama ya usemi tofauti wa sifa X katika kundi Y ni usemi wa wastani wa sifa X juu ya seli zote katika kundi Y iliyogawanywa na wastani wake juu ya seli zote katika makundi mengine (ukiondoa kundi Y, inayoonyeshwa kama log10). Alama juu ya sifuri inaonyesha kuongezeka kwa sifa fulani katika kundi fulani ikilinganishwa na makundi mengine. Mraba mweusi unaonyesha alama ya wastani ya usemi tofauti wa sifa zake (takwimu ni wastani juu ya jeni).
        <bold>
         g
        </bold>
        Ugrupishaji wa jeni na protini kulingana na kazi zao. Maelezo ya kila kundi na sifa zao zinazohusiana yanaonyeshwa.
        <bold>
         a
        </bold>
        ,
        <bold>
         c
        </bold>
        –
        <bold>
         f
        </bold>
        Uchambuzi wa uwakilishi wa seli kutoka kwa mfadhili D1.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Kuondoa kipingamizi cha kinga NKG2A kunaboresha shughuli ya kupambana na AML ya seli za CAR33-NK katika majaribio ya vitro
    </title>
    <p id="Par11">
     Ili kutathmini kama kupunguzwa kwa usemi wa NKG2A kwenye uso wa seli za CAR33-NK, ambazo zilidumisha hali yao ya kuamilishwa na kukomaa (Figs.
     <xref ref-type="fig" rid="Fig2">
      2
     </xref>
     ,
     <xref ref-type="fig" rid="Fig3">
      3
     </xref>
     ), kungepelekea kuongezeka kwa uwezo wa cytotoxic wa seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK, tulichambua uwezo wao wa kuua dhidi ya seli za AML zinazosema HLA-E na CD33, kama vile mstari wa seli za AML OCI-AML2 na seli za msingi za mlipuko zilizotokana na mgonjwa (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4a
     </xref>
     na
     <xref ref-type="supplementary-material" rid="MOESM1">
      S5
     </xref>
     ). Kwa kweli, seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilionyesha uwezo bora wa cytotoxic katika uwiano tofauti wa effector-to-target (E:T), ikilinganishwa na seli za NT-,
     <italic>
      KLRC1
     </italic>
     - au CAR33-NK katika majaribio ya kuua kwa mtiririko wa seli kwa muda mfupi (4 h) na usiku kucha (24 h) (Fig.
     <xref ref-type="fig" rid="Fig4">
      4a
     </xref>
     ) pamoja na katika uchambuzi wa seli hai wa muda mrefu (Fig.
     <xref ref-type="fig" rid="Fig4">
      4b, c
     </xref>
     ). Uwezo wa kuua ulioongezeka wa seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ulionyeshwa zaidi katika uchunguzi wa IncuCyte wa saa 24, ambapo co-incubation ya seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK na seli za leukemic za GFP OCI-AML2 (kijani) ilisababisha uundaji wa makundi ya apoptotic ya seli za leukemic zilizotiwa rangi ya Annexin V (nyekundu), ambazo zilikuwa chache sana wakati seli za OCI-AML2 ziliposhindana na seli za NT-NK (picha za uwakilishi Fig.
     <xref ref-type="fig" rid="Fig4">
      4c
     </xref>
     , Supplementary Movies
     <xref ref-type="supplementary-material" rid="MOESM4">
      1
     </xref>
     –
     <xref ref-type="supplementary-material" rid="MOESM8">
      5
     </xref>
     ). Ili kuchunguza kama hali ya kuamilishwa ya seli za CAR33- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ilikuwa inahusishwa na uzalishaji wa perforin/granzyme ulioongezeka na uanzishaji wa ishara za apoptotic katika seli lengwa, uchambuzi wa western blot wa caspases katika seli za OCI-AML2 zilizookoka na kuchaguliwa kufuatia mawasiliano ya seli za NK ulifanywa. Tuligundua kuongezeka kwa Caspase-3 na Caspase-9 cleavage katika seli za OCI-AML2 ambazo zilinusurika mikutano ya seli za CAR33- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK, ikionyesha uanzishaji wa kifo cha seli kinachosimamiwa na caspase (Fig.
     <xref ref-type="fig" rid="Fig4">
      4d
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4a, b
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
     </sup>
     . Uchambuzi wa qPCR wa NK seli ulionyesha kuongezeka kwa usemi wa granzyme B katika seli za CAR33- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK kufuatia incubation ya saa 2 na seli za OCI-AML2 (Fig.
     <xref ref-type="fig" rid="Fig4">
      4e
     </xref>
     ).
     <italic>
      KLRC1
     </italic>
     - na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli zilichaguliwa kwa seli za NKG2A ili kutathmini kama zingekuwa na uwezo wa kuua ulioongezeka. Kama udhibiti,
     <italic>
      KLRC1
     </italic>
     - na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli zilichaguliwa kwenye seli za CD56 ili kuondoa athari zinazotegemea kuchagua. Katika majaribio ya cytotoxicity ya saa 4 na 24, seli za NKG2A zilizochaguliwa,
     <italic>
      KLRC1
     </italic>
     - na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK hazikuonyesha kuongezeka kwa kuua seli za OCI-AML2, ikilinganishwa na idadi ya seli za
     <italic>
      KLRC1
     </italic>
     -NK zisizochaguliwa zenye takriban 50% ya seli za NKG2A, ikionyesha kwamba kupunguzwa kwa 50% kwa usemi wa NKG2A kulitosha kuondoa mhimili wa kuzuia wa NKG2A-HLA-E (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4c
     </xref>
     )
     <sup/>
     .
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="en">
       <title>
        KO ya kipokezi kinachozuia NKG2A (
        <italic>
         KLRC1
        </italic>
        ) inakuza shughuli ya kupinga-AML ya seli za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK in vitro.
       </title>
       <p>
        <bold>
         a
        </bold>
        Jaribio la muda mfupi (4 h) na muda mrefu (24 h) la kuua seli za NK dhidi ya seli za CD33
        <sup>
         +
        </sup>
        /HLA-E
        <sup>
         +
        </sup>
        OCI-AML2 katika uwiano wa E:T ulioonyeshwa (
        <italic>
         n
        </italic>
        = 5). Wastani ± SD.
        <bold>
         b
        </bold>
        Ufuatiliaji wa nguvu wa kuua kwa CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK kwa kutumia picha ya IncuCyte-S3. Seli za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zilishirikishwa na seli za GFP
        <sup>
         +
        </sup>
        OCI-AML2 kwa 26.5 h na utoaji wa mwanga wa floresensi ulipimwa kwa muda (hali ya OCI-AML2 pekee
        <italic>
         n
        </italic>
        = 3; wengine
        <italic>
         n
        </italic>
        = 4). Wastani + anuwai.
        <bold>
         c
        </bold>
        Picha za uwakilishi zilizochukuliwa baada ya 24.5 h ya uchambuzi wa IncuCyte wa NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK seli zilizoshirikishwa na seli za GFP
        <sup>
         +
        </sup>
        OCI-AML2 (E:T = 0.5:1). Seli za uvimbe zinazoweza kuishi zinaonyeshwa kwa kijani kulingana na usemi wao wa GFP. Seli za uvimbe zinazokufa zinawekwa alama nyekundu kwa kuchora Annexin V. Kwa upigaji picha, jukwaa la IncuCyteS3 lilitumika.
        <bold>
         d
        </bold>
        Uchambuzi wa kukatwa kwa caspase katika seli za OCI-AML2 zilizookoka na kupangwa kufuatia ushirikiano wa seli za NK kwa 2 h ulifanywa kwa kutumia blot ya magharibi (jaribio moja la uwakilishi kati ya 3 linaonyeshwa; “clvd” = “cleaved”, “ctrl” = “control”).
        <bold>
         e
        </bold>
        Uchambuzi wa usemi wa jeni wa qPCR wa NT-,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -, CAR33- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK seli kufuatia ushirikiano wa 2 h na seli za OCI-AML2 (E:T = 3:1) (
        <italic>
         n
        </italic>
        = 5). Wastani wa triplicates za kiufundi ± SD. Uchambuzi wa takwimu ulifanywa kwa ANOVA ya njia mbili (
        <bold>
         a
        </bold>
        ), mtihani wa
        <italic>
         t
        </italic>
        wa Wanafunzi waliooanishwa (
        <bold>
         b
        </bold>
        ), Wilcoxon iliyoambatanishwa (
        <bold>
         e
        </bold>
        ). Kiumbe cha
        <italic>
         n
        </italic>
        ni nakala za kibaolojia (kutoka kwa wafadhili tofauti wa afya) (
        <bold>
         a
        </bold>
        ,
        <bold>
         b
        </bold>
        ,
        <bold>
         e
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     HLA-E ni lengo lililoonyeshwa kwa usawa kwa wagonjwa wa AML na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK zilionyesha uwezo bora wa kuua dhidi ya seli za mlipuko zilizotokana na mgonjwa ex vivo
    </title>
    <p id="Par12">
     Ili kushughulikia zaidi kama NKG2A knockout CAR33-NK seli zilikuwa na ufanisi ulioboreshwa dhidi ya nyenzo za mgonjwa wa msingi, seli za uboho (BMCs) zilizotokana na wagonjwa kumi tofauti wa AML wenye kuingizwa kwa mlipuko mkubwa (&gt;90% CD45 AML blasts) ziliwekwa pamoja kwa masaa 4 na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilizotengenezwa kutoka kwa wafadhili wenye afya tofauti (jumla
     <italic>
      n
     </italic>
     = maandalizi 20 tofauti ya wafadhili, Fig.
     <xref ref-type="fig" rid="Fig5">
      5a
     </xref>
     ). Tuliona kwamba HLA-E inasemwa kwa kiasi kikubwa kwa usawa katika wagonjwa wa AML bila uhusiano mkubwa kati ya vikundi vidogo tofauti (kikundi
     <italic>
      n
     </italic>
     = 177, Fig.
     <xref ref-type="fig" rid="Fig5">
      5b–d
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
     </sup>
     . Usemi wa HLA-E haukutabiri uwezekano wa kuishi kwa jumla (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S5a
     </xref>
     ). BMCs zote zilizotokana na wagonjwa wa AML zilithibitishwa kwa kutumia flow cytometry kwa CD33 positivity na dim hadi juu HLA-E (mtoaji wa uwakilishi umeonyeshwa kwenye Fig.
     <xref ref-type="fig" rid="Fig5">
      5e
     </xref>
     ; mkakati wa gating Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S5b
     </xref>
     )
     <sup/>
     .
     <fig id="Fig5" position="float">
      <label>
       Fig. 5
      </label>
      <caption xml:lang="en">
       <title>
        HLA-E ni lengo linaloonyeshwa kwa usawa kwa wagonjwa wa AML na seli za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zilionyesha uwezo wa juu wa kuua seli za milipuko zilizotokana na mgonjwa ex vivo.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mpango wa mtiririko wa kazi kwa maandalizi ya mgonjwa wa AML na kuunganishwa na seli za NK za wafadhili wenye afya ikifuatiwa na usomaji wa kazi wa seli za uboho wa mfupa (BM) zilizotokana na mgonjwa.
        <bold>
         b
        </bold>
        Mchoro wa nafasi ya viwango vya tofauti (CV). Kila nukta ni CV ya protini iliyoorodheshwa kwa mpangilio wa kuongezeka. HLA-E imeangaziwa.
        <bold>
         c
        </bold>
        Mchoro wa kutawanya wa PCA wa vipengele viwili vya kwanza vya kimsingi (PCs) vilivyopakwa rangi kwa nguvu ya HLA-E. Kila nukta ni sampuli.
        <bold>
         d
        </bold>
        Ramani ya joto ya thamani zilizorekebishwa kutoka kwa mtihani wa Kruska–Wallis usio wa parametric ikilinganishwa na nguvu ya HLA-E katika makundi: de novo AML (de novo vs. sekondari vs. inayohusiana na tiba, adj.
        <italic>
         p
        </italic>
        -value = 1.0), NPM1 (iliyobadilishwa vs. aina ya mwitu, adj.
        <italic>
         p
        </italic>
        -value = 1.0), FLT3 (ITD vs. TKD vs. aina ya mwitu, adj.
        <italic>
         p
        </italic>
        -value = 1.0), FAB (MO hadi M7, adj.
        <italic>
         p
        </italic>
        -value = 1.0), Kundi la umri (&lt;50 vs. 50-65 vs. &gt;65, adj.
        <italic>
         p
        </italic>
        -value = 1.0), ELN 2017 (inayopendeza vs. ya kati vs. mbaya, adj.
        <italic>
         p
        </italic>
        -value = 1.0), Jinsia (mwanamke vs. mwanaume, adj.
        <italic>
         p
        </italic>
        -value = 0.37).
        <bold>
         e
        </bold>
        Uonyeshaji wa CD33, uonyeshaji wa HLA-E na uonyeshaji wa CD45
        <sup>
         dim
        </sup>
        wa milipuko ya AML ya sampuli moja ya BMC ya msingi ya mgonjwa wa AML siku moja baada ya kuyeyuka (siku moja kabla ya kuunganishwa na seli za NK) zilichambuliwa kwa kutumia flow cytometry.
        <bold>
         f
        </bold>
        ,
        <bold>
         g
        </bold>
        Jaribio la kuua kwa kutumia flow cytometry kwa saa 4 la seli za NK dhidi ya nyenzo za mgonjwa wa AML wa msingi (
        <bold>
         f
        </bold>
        ) na nyenzo kutoka kwa wagonjwa walio na sehemu ndogo za molekuli zenye hatari kubwa (
        <bold>
         g
        </bold>
        ). Kwa sababu ya viwango vya juu vya sehemu ya lysis ya nyenzo za mgonjwa baada ya kuyeyuka, kuua maalum kwa seli za AML zinazoweza kuishi kunaonyeshwa. Wastani wa marudio ya kiufundi ya lysis ya seli za AML na wafadhili tofauti wa seli za NK (Wafadhili 1-20) zinaonyeshwa kwa kila mgonjwa wa AML #1–10 (
        <bold>
         f
        </bold>
        ,
        <bold>
         g
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig5_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par13">
     CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli zilionyesha uwezo bora wa kuua katika hali zote na wagonjwa ikilinganishwa na NT-,
     <italic>
      KLRC1
     </italic>
     - au CAR33-NK seli dhidi ya seli za mlipuko za AML kutoka kwa wagonjwa wote (Fig.
     <xref ref-type="fig" rid="Fig5">
      5f, g
     </xref>
     , jumla
     <italic>
      n
     </italic>
     = 10). Hii pia ni kweli kwa seli za mlipuko zilizotokana na wagonjwa wenye seti ndogo za hatari kubwa za molekuli (Fig.
     <xref ref-type="fig" rid="Fig5">
      5g
     </xref>
     , Jedwali la Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ,
     <italic>
      n
     </italic>
     = 6)
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     Uchambuzi wa CITE-seq wa seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK ulionyesha hali ya uanzishaji iliyohifadhiwa na shughuli iliyopunguzwa ya mzunguko wa seli baada ya mawasiliano na AML
    </title>
    <p id="Par14">
     Matokeo yetu ya awali yanaonyesha kwamba utangulizi wa CAR33 pamoja na kuondolewa kwa kipokezi cha kuzuia NKG2A kwa pamoja huongeza uwezo wa kuua wa seli za NK bila kusababisha mabadiliko makubwa ya usemi wa alama za uso au alama za uso katika mabwawa ya seli husika. Ili kuchunguza kama uwezo wa kuua wa antileukemia ulioboreshwa unaweza kuonyeshwa katika mabadiliko ya kifenotipu ya mabwawa ya seli za NK baada ya kukutana na seli za AML, tulifanya uchambuzi wa CITE-seq wa seli za NK zilizobadilishwa na zenye kazi (data za sumu ya seli zinaonyeshwa katika Fig. ya Ziada.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4d
     </xref>
     ) kufuatia utamaduni wa pamoja wa masaa 2 na seli za OCI-AML2 (E:T = 1:1). Seli za NK zilitenganishwa na seli za AML za GFP kwa kupanga seli kwa msingi wa cytometer ya mtiririko. Kama ilivyoelezwa hapo awali kwa uchambuzi wa CITE-seq kabla ya utamaduni wa pamoja, seli za NT-NK ziliwekwa kama GFP,
     <italic>
      KLRC1
     </italic>
     -NK seli kama GFP/NKG2A, CAR33-NK kama GFP/CAR- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli kama GFP/NKG2A/CAR seli (Fig.
     <xref ref-type="fig" rid="Fig6">
      6a
     </xref>
     ). Wakati data ya usemi wa seli za NK baada ya utamaduni wa pamoja ililinganishwa na ile kabla ya utamaduni wa pamoja, tuliona muundo wa kawaida wa mabadiliko katika usemi wa jeni na alama za uso ambao ulisababishwa katika mabwawa yote ya seli za NK (Fig.
     <xref ref-type="fig" rid="Fig6">
      6b, c
     </xref>
     ). Kuongezeka kwa juu zaidi kwa usemi baada ya kukutana na seli za leukemiki kulionekana kwa sitokini na kemokini, kama
     <italic>
      CSF2, CCL3
     </italic>
     ,
     <italic>
      CCL4
     </italic>
     , na TNF, kwa wasimamizi wa majibu ya kinga, kama
     <italic>
      IL3, IL1RN
     </italic>
     , CD69, na CD81, pamoja na wasimamizi wa unukuzi, kama
     <italic>
      MYC
     </italic>
     <bold>
      (
     </bold>
     Fig.
     <xref ref-type="fig" rid="Fig6">
      6b
     </xref>
     ). Viwango vya usemi wa
     <italic>
      FCGR3A
     </italic>
     /CD16 pamoja na
     <italic>
      TNFSF8
     </italic>
     vilipunguzwa baada ya mawasiliano ya AML katika mabwawa yote ya seli za NK (Fig.
     <xref ref-type="fig" rid="Fig6">
      6b, c
     </xref>
     ). Mabadiliko haya ya usemi yaliyosababishwa na kukutana na AML yalikuwa na nguvu zaidi katika seli za CAR33 na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK kuliko katika seli za NT na
     <italic>
      KLRC1
     </italic>
     -NK, mtawalia, ambayo inalingana na shughuli ya juu ya kuua ya mabwawa haya ya seli (Fig.
     <xref ref-type="fig" rid="Fig6">
      6c
     </xref>
     ). Seli za CAR33- na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK hazikuonyesha dalili za uchovu ulioongezeka kupitia mifumo kama vile kuongezeka kwa molekuli za kuzuia au za kuangalia kama
     <italic>
      HAVRC2
     </italic>
     (TIM3),
     <italic>
      TIGIT
     </italic>
     ,
     <italic>
      CD96
     </italic>
     ,
     <italic>
      PD-
     </italic>
     1 au
     <italic>
      CTLA-4
     </italic>
     kulingana na uchambuzi wa qPCR kufuatia masaa 2 ya utamaduni wa pamoja na seli za OCI-AML2 (Fig. ya Ziada.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S6a
     </xref>
     )
     <sup/>
     .
     <fig id="Fig6" position="float">
      <label>
       Fig. 6
      </label>
      <caption xml:lang="en">
       <title>
        Seli za CAR33- na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK zinaonyesha hali ya uanzishaji iliyohifadhiwa na maelezo tofauti ya uonyeshaji wa jeni kufuatia mawasiliano na seli za AML.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mpango wa mkakati wa kupanga kwa uchambuzi wa seli moja ya NK baada ya kuunganishwa unaonyeshwa. Seli za CAR-NK ziliwekwa kwenye CAR
        <sup>
         +
        </sup>
        ,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK seli kwenye NKG2A
        <sup>
         -
        </sup>
        na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK seli kwenye CD33
        <sup>
         +
        </sup>
        /NKG2A
        <sup>
         -
        </sup>
        seli za NK baada ya kuunganishwa kwa saa 2 na seli za OCI-AML2.
        <bold>
         b
        </bold>
        Mabadiliko ya jumla ya usambazaji wa jeni (RNA) katika mabwawa yote ya seli za NK baada ya kuunganishwa na seli za OCI-AML2. Mchoro wa Volcano kama ilivyo kwenye Fig.
        <xref ref-type="fig" rid="Fig2">
         2
        </xref>
        <bold>
         b
        </bold>
        –
        <bold>
         d
        </bold>
        .
        <bold>
         c
        </bold>
        Ramani ya joto inayoonyesha mabadiliko ya logarithmic ya jeni na protini zilizochaguliwa zilizoonyeshwa tofauti baada ya mawasiliano na seli za OCI-AML2 ikilinganishwa na kabla ya mawasiliano katika kila bwawa la seli za NK. LogFC chanya inawakilisha kuongezeka kwa jeni baada ya kuunganishwa ikilinganishwa na uonyeshaji wake kabla ya kuunganishwa.
        <bold>
         d
        </bold>
        Uchanganuzi wa pamoja wa seli moja kutoka kwa mabwawa yote ya seli za NK baada ya kuunganishwa (uwakilishi wa t-SNE). Uchanganuzi wa Louvain kwenye matokeo ya PCA.
        <bold>
         e
        </bold>
        Mchoro wa nukta unaoonyesha uonyeshaji wa jeni na alama za uso za maslahi katika sehemu ndogo 6 za seli za NK baada ya kuunganishwa na seli za OCI-AML2. Skeli ya rangi: kipimo ni wastani wa maadili ya uonyeshaji yaliyobadilishwa kwa log.
        <bold>
         f
        </bold>
        Wingi wa jamaa wa seli zinazohusiana na sehemu ndogo 6 kama sehemu ya mabwawa ya seli za NK baada ya kuunganishwa. Kwa kila bwawa la seli za NK (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK), wingi wa jamaa juu ya makundi yote unajumlisha hadi moja.
        <bold>
         g
        </bold>
        Thamani za uonyeshaji wa
        <italic>
         IFNG
        </italic>
        ,
        <italic>
         TOP2A
        </italic>
        na
        <italic>
         AURKB
        </italic>
        zinalinganishwa kati ya hali 4 (NT-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK) za mabwawa tofauti ya seli za NK kabla na baada ya kuunganishwa na seli za OCI-AML2.
        <bold>
         h
        </bold>
        Ramani ya joto inayoonyesha mabadiliko ya logarithmic ya IFNG, TOP2A na AURKB na protini baada ya mawasiliano na seli za OCI-AML2 ikilinganishwa na kabla ya mawasiliano ya seli za NK katika kila bwawa la seli za NK (kama ilivyo kwenye (
        <bold>
         c
        </bold>
        )).
        <bold>
         i
        </bold>
        Viwango vya INF-γ katika supernatants ya kuunganishwa kwa saa 4 ya seli za NK na OCI-AML2 (
        <italic>
         n
        </italic>
        = 3, marudio ya kibaolojia kutoka kwa wafadhili wenye afya tofauti).
        <bold>
         j
        </bold>
        Uchambuzi wa uonyeshaji wa vipokezi vya seli za NK baada ya saa 24 za kuunganishwa na seli za uvimbe za OCI-AML zilipimwa kwa kutumia flow cytometry (
        <italic>
         n
        </italic>
        = 3 wafadhili). Wastani ± SD. (
        <bold>
         b
        </bold>
        ) inaonyesha data iliyounganishwa kwa wafadhili D1 na D2. (
        <bold>
         c
        </bold>
        –
        <bold>
         g
        </bold>
        ) inaonyesha uchambuzi wa uwakilishi wa seli kutoka kwa wafadhili D1. Uchambuzi wa takwimu ulifanywa kwa kutumia mtihani wa
        <italic>
         t
        </italic>
        wa Wanafunzi walio na jozi (
        <bold>
         i
        </bold>
        ) na ANOVA ya njia mbili (
        <bold>
         j
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig6_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par15">
     Kisha tulichambua muundo wa seli moja wa mabwawa tofauti ya seli za NK baada ya utamaduni wa pamoja na seli za AML ili kusoma tofauti katika mabadiliko yaliyosababishwa na uanzishaji wa seli za NK. Sawa na kile tulichoona katika mabwawa ya seli za NK kabla ya utamaduni wa pamoja, muundo wa bwawa la
     <italic>
      KLRC1
     </italic>
     -NK ulifanana na ule wa bwawa la NT-NK na muundo wa bwawa la CAR33-NK ulikuwa zaidi kulinganishwa na bwawa la seli la CAR33-
     <italic>
      KLRC1
     </italic>
     -NK (Fig.
     <xref ref-type="fig" rid="Fig6">
      6d
     </xref>
     ). Wakati sampuli hizi za seli zilipowekwa kulingana na maelezo yao ya usemi wa jeni na alama za uso, tuliona kwamba makundi ya unukuzi yenye viwango vya juu zaidi vya jeni zilizochochewa na utamaduni wa pamoja, yaani
     <italic>
      CCL4, CCL3, IFNG, TNF
     </italic>
     , na
     <italic>
      MYC
     </italic>
     (Fig.
     <xref ref-type="fig" rid="Fig6">
      6d–f
     </xref>
     , kundi 1 na 4), yaliongezeka katika seli za CAR33-NK na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ikilinganishwa na maandalizi mengine ya seli za NK. Wingi wa juu wa seli hizi zinazotoa IFN-γ (kundi la unukuzi 1), na hivyo viwango vya juu vya IFN-γ katika supernatants za utamaduni wa pamoja wa masaa 4 vilionekana katika seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK baada ya utamaduni wa pamoja (Fig.
     <xref ref-type="fig" rid="Fig6">
      6e–i
     </xref>
     ) ikilinganishwa na seli za CAR33-NK, kulingana na matokeo kwamba bwawa hili la seli lilisababisha uwezo wa juu zaidi wa kuua
     <sup/>
     .
    </p>
    <p id="Par16">
     Mbali na tofauti katika usemi wa IFN-γ, tuliona kwamba seli zinazotoa jeni zinazotegemea mzunguko wa seli (DNA topoisomerase II alpha (
     <italic>
      TOP2A
     </italic>
     ), aurora kinase B (
     <italic>
      AURKB
     </italic>
     ) na
     <italic>
      TYMS
     </italic>
     , Fig.
     <xref ref-type="fig" rid="Fig6">
      6e–h
     </xref>
     , kundi la unukuzi 2) ziliongezeka katika seli za CAR33-NK ambazo hazikuwa na kuondolewa kwa
     <italic>
      KLRC1
     </italic>
     . Licha ya ukweli kwamba utamaduni wa pamoja na seli za AML ulisababisha kupungua kwa jumla kwa usemi wa jeni zinazotegemea mzunguko wa seli (Fig.
     <xref ref-type="fig" rid="Fig6">
      6h
     </xref>
     ), tuliweza kuona majaribio ya kiwango cha juu cha uzalishaji wa seli za CAR33-NK ikilinganishwa na ile ya seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK kufuatia mawasiliano ya seli za AML kwa viwango tofauti vinavyotegemea wafadhili (mfadhili mmoja wa uwakilishi umeonyeshwa katika Fig. ya Ziada.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S6b
     </xref>
     ). Katika kiwango cha kifenotipu tuliona hali iliyoamilishwa zaidi baada ya masaa 24 ya kuingiliana na seli za OCI-AML2 kwa alama ya uanzishaji CD69 na viwango vya juu vya usemi wa DNAM1, NKG2D (Fig.
     <xref ref-type="fig" rid="Fig6">
      6j
     </xref>
     ). Idadi kubwa ya seli za NK zilionekana ambazo zilionyesha alama za kuangalia kinga kama PD-1 na TIM-3, na seli zote za CAR33-NK na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilionyesha usemi wa TIGIT ulioongezeka baada ya mawasiliano ya seli za AML (Fig.
     <xref ref-type="fig" rid="Fig6">
      6j
     </xref>
     )
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     Nambari ndogo za seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK zinaweza kuondoa seli za kuanzisha leukemia zilizoko kwenye uboho
    </title>
    <p id="Par17">
     Baada ya kuona shughuli kali ya anti-AML na tabia ya sumu ya seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK in vitro, tulilenga kutathmini shughuli ya seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK in vivo (Fig.
     <xref ref-type="fig" rid="Fig7">
      7
     </xref>
     ). Tulitumia mfano wa panya wa OCI-AML2-xenograft NOD.Cg-
     <italic>
      Prkdc
     </italic>
     <italic>
      Il2rg
     </italic>
     Tg (CMV-IL3, CSF2, KITLG)1Eav/MloySzJ (NSG-SGM3) ulioelezwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     . Panya wa NSG-SGM3 huzalisha IL-3, GM-CSF na kipengele cha seli shina (SCF) kwa njia ya kikatiba, ambayo inaonyesha hali za kisaikolojia zaidi za mwenyeji wa binadamu na inakuza upandikizaji wa seli za AML
     <sup>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      ,
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
     </sup>
     . Hapo awali, tulitumia mara 3 dozi ndogo za seli za NK 5 × 10 ili kutathmini kama sumu ya seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK iliyoimarishwa in vitro katika viwango vya chini vya E:T inaweza kutafsiriwa katika mfano wa awali wa in vivo. Panya wa NSG-SGM3 walipokea seli za OCI-AML2 0.5 × 10 (GFP, Luciferase (Luc)) kwa njia ya mishipa, ikifuatiwa na utawala wa NT-,
     <italic>
      KLRC1
     </italic>
     -, CAR33-, au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli siku ya tatu, saba na kumi baada ya sindano ya seli za AML au kubaki bila kutibiwa (UT) (
     <italic>
      n
     </italic>
     = 4–9 panya/kikundi; Fig.
     <xref ref-type="fig" rid="Fig7">
      7a, b
     </xref>
     ). Matibabu na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK yalisababisha kupungua kwa nguvu kwa mzigo wa leukemiki siku ya 9–17, wakati panya waliopokea NT-,
     <italic>
      KLRC1
     </italic>
     -, au seli za CAR33-NK walionyesha tu kupungua kidogo kwa mzigo wa AML ikilinganishwa na wanyama wasiotibiwa (Fig.
     <xref ref-type="fig" rid="Fig7">
      7b, c
     </xref>
     ). Baada ya uteuzi na kuondolewa kwa panya wawili kwa kila kikundi kwa majaribio ya upandikizaji upya wa uboho wa mfupa (BM), wanyama waliobaki walichambuliwa katika jaribio la kuishi hadi siku ya 36 (Fig.
     <xref ref-type="fig" rid="Fig7">
      7d
     </xref>
     ). Wanyama waliotibiwa na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK walionyesha kuishi kwa muda mrefu zaidi kuliko wanyama waliotibiwa na seli za CAR33- na
     <italic>
      KLRC1
     </italic>
     -NK (Fig.
     <xref ref-type="fig" rid="Fig7">
      7d
     </xref>
     ). Baada ya uchunguzi huu wa ufanisi mkubwa wa antileukemiki in vivo na dozi 3 za chini za seli za NK 5 × 10, tulipunguza zaidi dozi za seli za NK na mzunguko wa sindano hadi mara 2 ya matumizi ya seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK 3 × 10 (Fig.
     <xref ref-type="fig" rid="Fig7">
      7e
     </xref>
     ). Tena, panya wa NSG-SGM3 walipokea seli za OCI-AML2 0.5 × 10 (GFP, Luc) kwa njia ya mishipa, ikifuatiwa na matumizi ya NT-,
     <italic>
      KLRC1
     </italic>
     -, CAR33-, au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli siku ya tatu na siku ya kumi baada ya sindano ya seli za AML (
     <italic>
      n
     </italic>
     = 3–4 panya/kikundi; Fig.
     <xref ref-type="fig" rid="Fig7">
      7e
     </xref>
     ). Inashangaza, matibabu na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK yalisababisha kupungua kwa nguvu kwa mzigo wa leukemiki siku ya 7–17, wakati panya waliopokea NT-,
     <italic>
      KLRC1
     </italic>
     -, au seli za CAR33-NK walionyesha tu kupungua kidogo kwa mzigo wa AML ikilinganishwa na wanyama wasiotibiwa (Fig.
     <xref ref-type="fig" rid="Fig7">
      7f, g
     </xref>
     ). Kisha, tulilenga kuthibitisha kutokuwepo kwa mlipuko wa AML na pia seli zinazoanzisha leukemia kwa panya ambao hawakuwa na ishara ya luciferase katika uboho wa mfupa (Fig.
     <xref ref-type="fig" rid="Fig7">
      7h-j
     </xref>
     ). Kwa madhumuni haya, majaribio ya uhamisho wa BM na upandikizaji upya yalifanywa kutoka kwa jumla ya wanyama 4 waliotibiwa na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK (Fig.
     <xref ref-type="fig" rid="Fig7">
      7h
     </xref>
     ) kulingana na mpango ufuatao: seli za BM zilitengwa, zikachanganywa na seli 5 × 10 zilipigwa mishipa kwa panya wapya (NSG-SGM3) kwa kila kikundi cha matibabu (Fig.
     <xref ref-type="fig" rid="Fig7">
      7i
     </xref>
     ). Wanyama waliopandikizwa upya wa BM walipimwa kila wiki, na mzigo wa leukemiki ulitathminiwa kwa upigaji picha wa bioluminescence (BLI). Panya waliopokea BM kutoka kwa wanyama waliotibiwa na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK hawakuonyesha ukuaji wa seli za leukemiki ikilinganishwa na panya waliotibiwa na seli za
     <italic>
      KLRC1
     </italic>
     - na CAR33-NK (Fig.
     <xref ref-type="fig" rid="Fig7">
      7i
     </xref>
     ). Katika kikundi cha uhamisho wa BM kutoka kwa panya waliotibiwa na seli za
     <italic>
      KLRC1
     </italic>
     -NK, mmoja kati ya sita, na kutoka kwa wanyama waliotibiwa na seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK, wanyama watano kati ya watano walibaki bila leukemia hadi siku ya 120 baada ya upandikizaji, wakati jaribio lilipomalizika
     <bold>
      (
     </bold>
     Fig.
     <xref ref-type="fig" rid="Fig7">
      7i
     </xref>
     ). Uchambuzi wa ugonjwa wa mabaki ya chini (MRD) wa panya waliopandikizwa upya kwa muda mrefu wa kundi la seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ulionyesha matokeo hasi katika uchambuzi wa cytometry ya mtiririko na uchambuzi wa microscopy ya confocal (wanyama watatu wa mfano, Fig. ya Ziada.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S7a, b
     </xref>
     ). Kwa ujumla, kufuatia sindano zote tatu na za kurudia za seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK, wanyama hawakuonyesha dalili za kupoteza uzito au mabadiliko katika mwonekano au tabia ambayo ilionyesha uvumilivu mzuri wa bidhaa ya CAR33-
     <italic>
      KLRC1
     </italic>
     -NK iliyotumika. Uchambuzi wa histolojia wa ini, mapafu, na tishu za koloni haukuonyesha dalili za GvHD au uharibifu mwingine wa viungo unaosababishwa na tiba kufuatia utawala mara mbili wa seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK (Fig. ya Ziada.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S8a
     </xref>
     ). Zaidi ya hayo, tathmini ya sitokini katika seramu ya panya siku ya kwanza na siku ya 15 baada ya sindano ya seli za NK ilionyesha viwango vya chini vya mfumo wa IL-10 ya binadamu, uzalishaji wa IL-6 wa panya wa NSG-SGM3 (Fig. ya Ziada.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S8b
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
     </sup>
     .
     <fig id="Fig7" position="float">
      <label>
       Fig. 7
      </label>
      <caption xml:lang="en">
       <title>
        Dozi ndogo za seli za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK katika mfano wa panya wa OCI-AML2-xenograft NSG-SGM3 zinaonyesha ufanisi ulioboreshwa ikilinganishwa na
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK au seli za CAR33-NK.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mpango wa tathmini ya in vivo ya matibabu ya sindano tatu na seli za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK (dozi tatu na seli 5 × 10
        <sup>
         6
        </sup>
        kwa njia ya mishipa) pamoja na matibabu ya chini ya ngozi na IL-2 katika mfano wa panya wa OCI-AML2 (Luc
        <sup>
         +
        </sup>
        ) xenograft NSG-SGM3.
        <bold>
         b
        </bold>
        Picha za BLI za panya wa OCI-AML2 (Luc
        <sup>
         +
        </sup>
        ) waliopandikizwa NSG-SGM3 waliotibiwa tofauti kwa muda (
        <italic>
         n
        </italic>
        = 4–9). Panya walipokea dozi tatu za seli 5 × 10
        <sup>
         6
        </sup>
        za NK siku ya 3, siku ya 7 na siku ya 10 baada ya sindano ya seli za AML.
        <bold>
         c
        </bold>
        Uchambuzi wa mtiririko wa jumla (fotoni/sekunde) wa panya (
        <italic>
         n
        </italic>
        = 4–9). Wastani ± SD.
        <bold>
         d
        </bold>
        Uhai na mzigo wa leukemiki wa panya waliopandikizwa OCI-AML2 ulizingatiwa kwa siku 36.
        <bold>
         e
        </bold>
        Mpango wa tathmini ya in vivo ya matibabu ya sindano mbili na seli za CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK (dozi mbili na seli 3 × 10
        <sup>
         6
        </sup>
        kwa njia ya mishipa) pamoja na matibabu ya chini ya ngozi na IL-2 katika mfano wa panya wa OCI-AML2 (Luc
        <sup>
         +
        </sup>
        ) xenograft NSG-SGM3.
        <bold>
         f
        </bold>
        Picha za BLI za panya wa OCI-AML2 (Luc
        <sup>
         +
        </sup>
        ) waliopandikizwa NSG-SGM3 waliotibiwa tofauti kwa muda (
        <italic>
         n
        </italic>
        = 3–4). Panya walipokea dozi mbili za seli 3 × 10
        <sup>
         6
        </sup>
        za NK siku ya 3 na siku ya 10 baada ya sindano ya seli za AML.
        <bold>
         g
        </bold>
        Uchambuzi wa mtiririko wa jumla (fotoni/s) wa panya (
        <italic>
         n
        </italic>
        = 3–4). Wastani ± SD.
        <bold>
         h
        </bold>
        Mpango wa jaribio la upandikizaji upya wa uboho wa mfupa (BM) in vivo. Seli za BM za wanyama waliotibiwa na NK (ambao hawajatibiwa hapo awali (UT), zisizo na transduced (NT)-NK,
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK, CAR33-NK na CAR33-
        <italic>
         KLRC1
        </italic>
        <sup>
         ko
        </sup>
        -NK wanyama waliotibiwa) zilitengwa siku ya 18, zikachanganywa, na kuingizwa kwenye panya wapya wa NSG-SGM3 (seli 5 × 10
        <sup>
         6
        </sup>
        /mnyama;
        <italic>
         n
        </italic>
        = 2–6).
        <bold>
         i
        </bold>
        Uhai na mzigo wa leukemiki wa panya waliopandikizwa upya BM ulizingatiwa kwa siku 120 (itifaki ya wanyama: mwisho wa jaribio).
        <bold>
         j
        </bold>
        Uchambuzi wa uwakilishi wa microscopy ya confocal ya seli za AML za GFP
        <sup>
         +
        </sup>
        katika histolojia ya BM siku ya 18 baada ya sindano ya seli za AML. Uchambuzi wa takwimu ulifanywa kwa kutumia ANOVA ya njia mbili (
        <bold>
         c
        </bold>
        ,
        <bold>
         g
        </bold>
        ) na Kaplan–Meier (Mtihani wa Log-rank (Mantel–Cox)) (
        <bold>
         d
        </bold>
        ,
        <bold>
         i
        </bold>
        ).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52388-1/41467_2024_52388_Fig7_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
  </sec>
  <sec id="Sec9" sec-type="discussion">
   <title>
    Majadiliano
   </title>
   <p id="Par18">
    Matumizi ya kliniki ya seli za msingi za CAR-NK ni njia ya tiba ya seli inayovutia kwa ajili ya tiba salama na yenye ufanisi. Katika majaribio ya kliniki ya Awamu ya I/II, seli za CAR-NK zinazolenga CD19 za allogenic zilipata viwango vya majibu vinavyovutia kwa wagonjwa wenye magonjwa ya seli za B, pamoja na wasifu bora wa usalama bila kesi zilizoripotiwa za ugonjwa mkali wa kutolewa kwa cytokine (CRS), neurotoxicity, au ugonjwa wa kupandikiza dhidi ya mwenyeji (GvHD)
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR35">
      35
     </xref>
    </sup>
    . Matumizi ya seli za NK kwa ajili ya kizazi cha seli za athari za CAR hutoa faida zinazowezekana, hasa katika kesi ya antijeni za lengo ambazo hazijazuiliwa pekee kwa seli za saratani, kama ilivyo katika kesi ya AML
    <sup>
     <xref ref-type="bibr" rid="CR36">
      36
     </xref>
    </sup>
    . Katika tafiti za majaribio, tiba ya kinga ya kupandikiza kwa AML na seli za NK zisizobadilishwa ilithibitishwa kuwa salama, na majibu ya mlipuko yalionekana kwa baadhi ya wagonjwa
    <sup>
     <xref ref-type="bibr" rid="CR37">
      37
     </xref>
    </sup>
    . Hasa, idadi ya seli za NK zilizoanzishwa na cytokine zinaonekana kuwa na uwezo wa kuzuia leukemia, na jukumu muhimu kwa kumbukumbu ya seli za NK zilizoanzishwa na IL-15 au IL-12/15/18
    <sup>
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
    </sup>
    . Hata hivyo, mazingira ya kinga ya leukemiki katika mfupa wa uboho na upinzani wa seli za leukemiki unaweza kupunguza ufanisi wa tiba za seli. Uchambuzi wa seli moja umeonyesha, ambao ulionyesha mwelekeo wa utofautishaji wa seli za NK katika mfupa wa uboho na saini ya mkazo katika AML, ambayo iliharibu sana kazi ya seli za NK
    <sup>
     <xref ref-type="bibr" rid="CR38">
      38
     </xref>
     ,
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
    </sup>
    . Muhimu, uwezo wa ndani wa kupambana na uvimbe wa seli za NK una uwezo wa kuondoa pia seli za uvimbe ambazo zimepoteza usemi wa antijeni ya lengo la CAR, ambayo bado haiwezekani katika tiba za seli za CAR-T
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
    </sup>
    . Zaidi ya hayo, viwango vya juu vya INF-γ iliyotolewa vinaweza kuathiri kazi ya kupambana na uvimbe ya seli za NK baada ya kuwasiliana na uvimbe
    <sup>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Viwango vya juu vya INF-γ iliyotolewa pia vilionekana kwa seli za CAR-NK zinazolenga CD33 baada ya kuwasiliana na seli za lengo katika AML, ambayo inaweza kusababisha kuongezeka kwa molekuli za kuzuia kama vile protini ya MHC I isiyo ya kawaida HLA-E
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Kwa hivyo, ufanisi wa kuzuia leukemia unaweza kuzuiwa kupitia vipokezi vya kuangalia kinga vya kuzuia kama NKG2A, ambavyo vinaunganishwa na HLA-E, mara nyingi huonyeshwa zaidi kwenye seli za uvimbe
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
    </sup>
    . Data za awali za kikundi chetu na wengine zilionyesha kuwa kuzuia HLA-E/NKG2A kunaweza kushindwa kwa kuzuia au mabadiliko ya CRISPR/Cas9 NKG2A
    <sup>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     ,
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Katika kazi hii, tunafafanua kizazi cha mafanikio cha seli za NK zilizobadilishwa mara mbili kwa kuchanganya kizazi cha CAR33 na usumbufu wa jeni wa CRISPR/Cas9 unaosimamiwa na
    <italic>
     KLRC1
    </italic>
    . Seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zilizotokana zilionyesha uwezo bora wa sumu dhidi ya seli za lengo za CD33/HLA-E ikilinganishwa na seli za CAR33-NK au seli za
    <italic>
     KLRC1
    </italic>
    -NK dhidi ya mistari ya seli za AML, seli za mlipuko wa AML zilizotokana na mgonjwa ex vivo na katika mfano wa xenograft ya panya ya AML in vivo
    <sup/>
    .
   </p>
   <p id="Par19">
    Ufanisi wa usemi wa CD33-CAR baada ya uhamishaji wa lentiviral ulikuwa sambamba na data zilizochapishwa hapo awali kwa uhamishaji wa lentiviral ulivyoripotiwa na kikundi chetu na wengine
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ,
     <xref ref-type="bibr" rid="CR40">
      40
     </xref>
     ,
     <xref ref-type="bibr" rid="CR41">
      41
     </xref>
    </sup>
    . Inafurahisha, asilimia ya seli za NK zenye CAR iliongezeka kwa muda (Fig.
    <xref ref-type="fig" rid="Fig1">
     1c
    </xref>
    ), ambayo inaweza kuhusishwa na uteuzi wa promota
    <sup>
     <xref ref-type="bibr" rid="CR42">
      42
     </xref>
     ,
     <xref ref-type="bibr" rid="CR43">
      43
     </xref>
    </sup>
    . Mara kwa mara ya usumbufu wa jeni wa CRISPR/Cas9 usio wa virusi wa
    <italic>
     KLRC1
    </italic>
    ulikuwa maalum sana na uchambuzi wa usambazaji wa Indel ulionyesha kuingizwa kwa +1 ikifuatiwa na kufutwa kwa −15 kwa uwepo au kutokuwepo kwa CAR na kufutwa kwa −15 kunaweza kuelezewa na uwepo wa mfuatano wa micro-homology unaozunguka tovuti ya kukata (Fig.
    <xref ref-type="fig" rid="Fig1">
     1f
    </xref>
    , Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S1c
    </xref>
    ,
    <xref ref-type="supplementary-material" rid="MOESM1">
     1d
    </xref>
    ). Uchambuzi wa kizazi kijacho wa upimaji (NGS) ulionyesha shughuli ndogo tu ya CRISPR/Cas9 nuclease katika seli za CAR-KO NK kwenye OT1 (~0.1%) ambayo ni sawa na ripoti za awali (Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S1c, d
    </xref>
    ). Hata hivyo, mbinu za jadi kama NGS zinaweza tu kugundua matukio yasiyotarajiwa ya genotoxic katika fomu ndogo ya kuingizwa/kufutwa (INDELs) lakini hazizingatii mabadiliko yote ya kimuundo ya jeni
    <sup>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
     <xref ref-type="bibr" rid="CR42">
      42
     </xref>
    </sup>
    . Teknolojia mpya kama CAST-seq huruhusu kugundua mabadiliko katika urekebishaji wa kromosomu nzima na inapaswa kuthibitisha uchambuzi wa jeni wa sasa, hata kama hatari ya mutajeni ni ndogo sana katika seli zilizotofautishwa kikamilifu
    <sup>
     <xref ref-type="bibr" rid="CR44">
      44
     </xref>
     ,
     <xref ref-type="bibr" rid="CR45">
      45
     </xref>
    </sup>
    .
   </p>
   <p id="Par20">
    Inafurahisha, ingawa mara kwa mara ya usumbufu wa jeni wa
    <italic>
     KLRC1
    </italic>
    (Fig.
    <xref ref-type="fig" rid="Fig1">
     1e
    </xref>
    ) ilifikiwa kwenye kiwango cha jeni, hii ilitafsiri tu kwa takriban 50% ya kupunguzwa kwa seli chanya za NKG2A (Fig.
    <xref ref-type="fig" rid="Fig1">
     1d
    </xref>
    ). Tunadhani kwamba kufutwa kwa nukleotidi −15 kwa sura inaweza kuwa kumechangia athari hii. Kufutwa kwa mabaki matano kunaweza kuzuia kazi ya NKG2A lakini si lazima usemi wake wa uso. Wakati kazi yetu ilionyesha kuwa idadi ya seli za CAR-NK zilizopangwa kuwa hasi kwa 100% NKG2A haziwezi kuongeza zaidi sumu katika vitro (Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S4c
    </xref>
    ), inabaki kufafanuliwa ikiwa kupunguzwa kwa nguvu kwa usemi wa phenotypic NKG2A ni muhimu katika muktadha wa kazi ya athari ya seli za NK, ambayo inadhibitiwa na usawa wa wasifu wa kipokezi cha uso wa seli kinachoamsha na kuzuia. Katika suala hili, ni muhimu kutambua kwamba usemi wa NKG2A uliobaki unaweza bado kuzuia shughuli za seli za CAR-NK in vivo, kutokana na uwezekano wa kuongezeka kwa HLA-E kwenye seli za uvimbe kufuatia kuwasiliana na IFN-γ iliyotolewa na seli za NK.
   </p>
   <p id="Par21">
    Katika kazi yetu ya awali ya kabla ya kliniki, tulizalisha seli za msingi za CAR33-NK zilizoanzishwa na IL-2/15 na kupanuliwa ambazo zilionyesha shughuli kali ya kuzuia leukemia dhidi ya seli za CD33 AML katika vitro na katika mfano wa xenograft in vivo
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
    </sup>
    . Viwango vya juu vya IFN-γ vinaweza kusababisha kuongezeka kwa HLA-E kwenye seli za uvimbe, ambayo pia imeonekana kufuatia tiba ya seli za CAR33-NK katika panya wanaobeba AML pamoja na katika seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK kufuatia kuwasiliana na seli za AML katika vitro (Fig.
    <xref ref-type="fig" rid="Fig6">
     6g, i
    </xref>
    )
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR46">
      46
     </xref>
    </sup>
    . Zaidi ya hayo, uchambuzi wa nyuma wa nyenzo za mgonjwa wa AML ulionyesha kuwa HLA-E inaonyeshwa kwa usawa kwenye seli za AML na haionekani kuhusiana na majibu ya kliniki (
    <italic>
     n
    </italic>
    = 177, Fig.
    <xref ref-type="fig" rid="Fig5">
     5b–d
    </xref>
    , Supplementary Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     S5a
    </xref>
    ). Uchunguzi huu unasisitiza umuhimu wa kliniki wa mhimili wa HLA-E/NKG2A na kuangazia dhana ya uhariri wa seli za NK ili kushinda kizuizi hiki cha kinga. Licha ya matibabu yenye uwezo wa kuponya kwa wagonjwa wenye leukemia kali ya hatari kubwa kwa kupandikiza seli za shina za hematopoietic za allogeneic, kurudi kwa ugonjwa kunabaki kuwa sababu kuu ya kifo na tiba mbadala zinahitajika haraka
    <sup>
     <xref ref-type="bibr" rid="CR47">
      47
     </xref>
     ,
     <xref ref-type="bibr" rid="CR48">
      48
     </xref>
    </sup>
    . Katika mwelekeo huu, maandalizi ya seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK kutoka kwa wafadhili mbalimbali wa allogenic yaliongeza kwa kiasi kikubwa ufanisi wa sumu tayari kwa idadi ndogo ya seli dhidi ya seli za mlipuko wa AML za msingi (HLA-E) zilizotokana na kundi la wagonjwa wenye genotype ya kawaida au ya hatari kubwa ya molekuli (Fig.
    <xref ref-type="fig" rid="Fig5">
     5f, g
    </xref>
    )
    <sup>
     <xref ref-type="bibr" rid="CR30">
      30
     </xref>
    </sup>
    .
   </p>
   <p id="Par22">
    Kwa lengo la kufichua zaidi mifumo ya msingi inayosababishwa na uhariri maalum wa jeni, tulifanya uchambuzi wa wasifu wa alama za uso na transcriptome ya seli za CAR33-NK zilizobadilishwa na CRISPR/Cas9. Kufuatia mwingiliano wa moja kwa moja na seli za AML, wasifu wa kuashiria wa chini wa CAR ulioongezeka, na kuongezeka kwa alama za uanzishaji na uhamaji zilionekana hasa katika idadi ya seli za CAR33- na CAR33-
    <italic>
     KLRC1
    </italic>
    -NK, ambayo inaweza kuelezea kuangamizwa kwa haraka na kwa kasi kwa seli za AML. Zaidi ya hayo, uchambuzi wa CITE-Seq ulionyesha wasifu wa transcriptional ulioainishwa kama saini ya IFN-γ Type-I-signaling inayopatikana zaidi katika seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK baada ya kufichuliwa kwa AML. Hii inalingana na tafiti nyingine za hivi karibuni zinazohusu uanzishaji wa IFN-γ baada ya kuwasiliana na aina mbalimbali za saratani ya damu
    <sup>
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
    </sup>
    .
   </p>
   <p id="Par23">
    Inashangaza, wakati wa kulinganisha bidhaa za seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK katika majaribio ya sumu ya seli ya saa 4 na 24 dhidi ya seli za OCI-AML2, seli za CAR33-NK zilionekana kuwa na uwezo wa kuua kwa muda mfupi unaosababishwa na ongezeko la kukatika kwa caspase-3 na utoaji wa perforin na granzyme, wakati seli za
    <italic>
     KLRC1
    </italic>
    -NK ziliongeza uwezo wao wa kuua katika mchakato wa muda mrefu (Fig.
    <xref ref-type="fig" rid="Fig4">
     4
    </xref>
    ). Muhimu, seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinanufaika na marekebisho ya ziada, hasa katika uwiano wa chini wa E:T, ambao unaakisi hali za kisaikolojia zinazowezekana kwa binadamu (Figs.
    <xref ref-type="fig" rid="Fig5">
     5
    </xref>
    ,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    )
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR48">
      48
     </xref>
     ,
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    . Wakati data za CITE-Seq zinaonyesha kwamba seli za CAR33- na CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinatumia mbinu sawa za kuua, mchanganyiko wa sumu ya muda mfupi na mrefu katika seli za NK zilizobadilishwa mara mbili unaonekana kuendeshwa na CAR na kudumishwa kupitia ukandamizaji wa kizuizi cha NKG2A. Hii inaweza kuwa muhimu kwa ufanisi wa seli za NK katika mazingira ya uvimbe yaliyo na IFN-γ/HLA-E nyingi
    <sup/>
    .
   </p>
   <p id="Par24">
    Majaribio yetu ya in vivo hayapendekezi kipimo bora cha mwisho lakini yanaweza kuthibitisha nguvu ya seli za NK zilizobadilishwa mara mbili kwa matibabu ya AML tayari na matumizi mawili ya dozi ndogo za seli 3 × 10 NK na ufanisi unaolingana baada ya mara tatu za seli 5 × 10 NK. Data za kliniki kutoka kwa majaribio ya hivi karibuni ya seli za CAR-NK kwa matibabu ya magonjwa ya seli B tayari zilionyesha kwamba athari kali zinaweza kupatikana kwa dozi ndogo za tiba ya seli
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    . Hata hivyo, hili linahitaji kuchunguzwa zaidi kwa tiba ya seli za NK zilizobadilishwa mara mbili inayolenga AML katika njia kuelekea tafsiri ya kliniki.
   </p>
   <p id="Par25">
    Marekebisho mara mbili ya seli za NK yanatoa uwezo mkubwa kwa bidhaa za seli za CAR-NK zilizoboreshwa, zilizoboreshwa ambazo pia zinafaa kupinga njia za kukandamiza kinga zaidi ya zile zinazoendeshwa na NKG2A. Kwa mfano, hivi karibuni imeripotiwa kwamba kuondolewa kwa protini ya
    <italic>
     CISH
    </italic>
    inayoweza kushawishiwa na cytokine katika seli za CAR-NK zinazotokana na damu ya kitovu kunaweza kuboresha "uwezo" wa kimetaboliki, kudumu kwa muda mrefu in vivo na sumu ya seli
    <sup>
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    . Hata hivyo, uhariri wa jeni wa ziada wa vizuizi vya kinga unahitaji kutathminiwa kwa uangalifu kwa ufanisi wao wa ziada wa kazi.
   </p>
   <p id="Par26">
    Kuhusu umuhimu wa njia ya upitishaji ishara inayosimamiwa na kipokezi cha TIGIT katika seli za NK, imeelezwa kuwa kuondolewa kwa TIGIT kunaweza kuboresha utendaji wa seli za NT-NK lakini si za seli za CAR-NK katika AML
    <sup>
     <xref ref-type="bibr" rid="CR50">
      50
     </xref>
    </sup>
    . Kinyume chake, athari iliyoboreshwa ya seli za CAR-NK zilizobadilishwa mara mbili za
    <italic>
     TIGIT
    </italic>
    -knockout iliripotiwa katika glioblastoma, ambayo inakubaliana kwa kushangaza na matokeo yetu kwa
    <italic>
     KLRC1
    </italic>
    ya seli za CAR-NK katika AML
    <sup>
     <xref ref-type="bibr" rid="CR51">
      51
     </xref>
    </sup>
    .
   </p>
   <p id="Par27">
    Katika tafsiri ya kliniki ya baadaye, mbinu ya uhariri wa jeni inazidi kuwa muhimu, kwani magonjwa ya saratani ya sekondari yameripotiwa ambayo yanaweza kuwa yametokana na bidhaa za seli za CAR-T zilizotengenezwa kwa virusi
    <sup>
     <xref ref-type="bibr" rid="CR52">
      52
     </xref>
    </sup>
    . Katika muktadha huu, mbinu za uhariri wa jeni zisizo za virusi kabisa zinaweza kupunguza hatari ya mabadiliko ya saratani katika tiba za seli za kinga za CAR
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
     ,
     <xref ref-type="bibr" rid="CR53">
      53
     </xref>
     ,
     <xref ref-type="bibr" rid="CR54">
      54
     </xref>
    </sup>
    .
   </p>
   <p id="Par28">
    Kwa ujumla, tulionyesha kwa mara ya kwanza kwamba seli za CAR33-
    <italic>
     KLRC1
    </italic>
    -NK zinawakilisha dhana mpya ya tiba ya seli za NK ambayo inaweza kushinda ukandamizaji wa kinga unaosababishwa na AML na inaonekana kuwa na ufanisi mkubwa na salama katika tathmini ya awali ya vivo. Marekebisho ya kijenetiki mara mbili kwa kuanzisha CAR na kuondoa kwa usahihi vipokezi vya vizuizi vya ukaguzi vina uwezo wa kuwezesha seli za NK kupita athari za ukandamizaji sio tu za AML, bali pia za aina nyingine nyingi za saratani
    <sup/>
    .
   </p>
  </sec>
  <sec id="Sec10" sec-type="methods">
   <title>
    Mbinu
   </title>
   <sec id="Sec11">
    <title>
     Taarifa ya maadili
    </title>
    <p id="Par29">
     Utafiti wote unaotumia vifaa vya binadamu uliidhinishwa na bodi ya mapitio ya maadili ya ndani (idhini namba 329/10 na 274/18) na ulifanywa kwa mujibu wa kanuni za Helsinki. Matumizi ya aspirati za uboho yaliidhinishwa na Kamati ya Maadili ya Hospitali ya Chuo Kikuu cha Frankfurt (idhini No. SHN-12-2016, marekebisho 01 2021 na 02 2022) na muungano wa utafiti wa leukemia (SAL, idhini No. EK98032010). Majaribio yote ya panya yaliidhinishwa na Regierungspräsidium Darmstadt, Ujerumani (FK1123).
    </p>
   </sec>
   <sec id="Sec12">
    <title>
     Seli za msingi za AML
    </title>
    <p id="Par30">
     BMCs za mgonjwa wa AML zilizohifadhiwa kwenye barafu ziliyeyushwa kwenye IMDM kati iliyoongezwa na 20% FBS na 1% penicillin/streptomycin na seli ziliwekwa kwa dakika 10 na 100 µg/ml DNAse I. Baadaye, seli zilioshwa na kukuzwa kwenye kati ya IMDM na L-glutamine na HEPES (Invitrogen) iliyoongezwa na 100 U/ml penicillin, 100 mg/ml streptomycin, 100 ng/ml stem cell factor (SCF), 20 ng/ml IL-3, 20 ng/ml IL-6 na 100 ng/ml FMS-like tyrosine kinase 3 ligand (FLT3L). Seli zilipandwa kwa msongamano wa seli wa 2×10 seli/ml kwenye sahani ya visima 12. Siku iliyofuata seli zilichambuliwa kwa uhai kupitia umbo (FSC/SSC) na 7-AAD-staining (BD Biosciences), milipuko ya AML ilihesabiwa kwa msingi wa usemi wa CD45dim kwa kutumia kingamwili za anti-CD45-APC (Clone 2D1, BD Biosciences), usemi wa CD33 kwa kutumia kingamwili za anti-CD33-BV421 (Clone WM53, BD Bioscience) na usemi wa HLA-E kwa kutumia kingamwili za anti-HLA-E-APC (Clone 3D12, Biolegend). Siku ya pili baada ya kuyeyuka, seli zilipandwa kwenye jaribio la sumu la saa 4 na seli za NK. Kwa sifa za kina za mgonjwa angalia Jedwali la Nyongeza
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     <sup/>
     . Matumizi ya vifaa vya msingi vya mgonjwa yaliidhinishwa na Tume ya Maadili ya Hospitali ya Chuo Kikuu cha Frankfurt, Ujerumani (idhini no. 274/18). Washiriki wote walitoa idhini iliyoandikwa kwa mujibu wa Azimio la Helsinki.
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     Utoaji wa seli za NK
    </title>
    <p id="Par31">
     Seli za NK zilitengwa kutoka kwenye makoti ya damu safi kutoka kwa wafadhili wenye afya, wasiojulikana waliotolewa na Msalaba Mwekundu wa Ujerumani wa Utoaji Damu (DRK-Blutspendedienst Baden-Württemberg-Hessen, Frankfurt am Main, Ujerumani) kama ilivyoelezwa awali
     <sup>
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
     </sup>
     . Kwa ufupi, seli za mononuklia za damu ya pembeni (PBMCs) zilitengwa kwa kutumia centrifugation ya gradient ya msongamano wa Ficoll (Biocoll, Biochrom) na utajiri wa seli za NK ulifanywa kwa kutumia Kit ya Utajiri wa Seli za Binadamu za NK (StemCell) kulingana na maelekezo ya mtengenezaji. Usafi wa seli za NK ulithibitishwa kwa uchambuzi wa flow cytometry. Mradi huu uliidhinishwa na Kamati ya Maadili ya Chuo Kikuu cha Goethe Frankfurt, Ujerumani (idhini no. 329/10).
    </p>
   </sec>
   <sec id="Sec14">
    <title>
     Uhifadhi wa baridi wa seli za NK zilizobadilishwa kijenetiki za allogeneic
    </title>
    <p id="Par32">
     Seli za msingi za NK kutoka kwenye makoti ya damu zilisafirishwa kwa 300
     <italic>
      g
     </italic>
     kwa dakika kumi. Supernatant iliondolewa, na seli ziliwekwa upya kwenye kati ya RPMI1640 baridi iliyoongezwa na 20% seramu ya ndama ya fetasi (FBS). Baadaye, kiasi sawa cha kati ya RPMI1640 iliyoongezwa na 20% Dimethyl sulfoxide (DMSO) iliongezwa kwa matone huku mchanganyiko wa seli ukiendelea kuchanganywa. Mkazo wa mwisho ulidumishwa kati ya (4–16) × 10 seli/ml. Mchanganyiko wa seli ulighifadhiwa kwenye -80 °C kwa kutumia chombo cha kugandisha cha Mr. Frosty (Thermo Fisher Scientific). Kwa uhifadhi wa muda mrefu seli zilihamishiwa kwenye nitrojeni ya kioevu
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     Ujenzi wa CAR na uzalishaji wa vekta ya lentiviral
    </title>
    <p id="Par33">
     CAR ya kizazi cha pili inayolenga CD33 ambayo inajumuisha mlolongo wa My96 scFv ilitumiwa kama ilivyoelezwa awali
     <sup>
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
     </sup>
     . My96 scFv iliunganishwa na hinge ya CD8 na kikoa cha transmembrane, kikoa cha ushirikiano wa 4-1BB/CD137, na kikoa cha uanzishaji cha CD3ζ. Peptidi ya kiongozi ikijumuisha promota inayotokana na GM-CSFRα iliongezwa. Vectors za lentiviral za kizazi cha tatu zilizojifunga zilitengenezwa kwa kutumia uhamisho wa muda mfupi katika seli za HEK293T kwa kutumia MACSfectin (Miltenyi Biotec) au polyethylenimine (PEI)
     <sup>
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     Uhamishaji wa seli za msingi za NK
    </title>
    <p id="Par34">
     Seli za NK zilihamishwa kama ilivyoelezwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     . Siku ya pili baada ya kutengwa kwa seli za NK, seli zilihamishwa na chembe za lentiviral kwa kushirikiana na Vectofusin-1 (Miltenyi Biotec; 2.5 µg/ml mkusanyiko wa mwisho). Mchanganyiko wa virusi na seli ulizungushwa kwa 400
     <italic>
      g
     </italic>
     kwa masaa 2 katika 32 °C. Masaa 24 baada ya uhamisho, nusu ya kati ilibadilishwa na kati safi. Baada ya uhamisho, seli za NK zilipandwa katika kati ya NK-MACS iliyoongezwa na 5% plasma ya binadamu, 1% NK-MACS Supplements, 1% Pen/Strep, 500 IU/ml IL-2 (Miltenyi Biotec au Novartis) na 10 ng/ml IL-15 (Miltenyi Biotec) au 50 ng/ml IL-15 (CellGenix)
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec17">
    <title>
     Nukleasi za CRISPR/Cas9 zinazolenga
     <italic>
      KLRC1
     </italic>
    </title>
    <p id="Par35">
     Seli za msingi za NK zilibadilishwa kwa kutumia mfumo wa CRISPR/Cas9 usio wa virusi kama ilivyoelezwa hivi karibuni
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Kwa ufupi, 1 × 10 seli za NK zisizohamishwa (NT)-NK au CAR (CAR33)-NK zilizoelekezwa kwa CD33 zilifanyiwa nucleofection (4D-Nucleofector; Lonza) baada ya wiki moja baada ya uhamisho au utamaduni wa ziada kwa kutumia kiasi cha Cas9:gRNA kulingana na itifaki ya nucleofection ya seli za NK iliyoboreshwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     . Seli zilipandwa na 1 × 10 seli/ml katika 500 µL ya kati ya utamaduni. Seli za CAR33-
     <italic>
      KLRC1
     </italic>
     -NK na seli za udhibiti zilipandwa kwa angalau siku 10 kufuatia nucleofection kabla ya kutumika katika majaribio ya kazi in vitro au in vivo
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec18">
    <title>
     Uchambuzi wa jenotipu wa seli za NK zilizohaririwa
    </title>
    <p id="Par36">
     Genotyping ya seli za NK zilizohaririwa
     <italic>
      KLRC1
     </italic>
     ilifanywa kwa kutumia T7 endonuclease I (T7E1, NEB) na kwa Uchambuzi wa Inference of CRISPR Edits (ICE) (Synthego Performance Analysis, ICE Analysis. 2019. V3.0). PCR amplicon ya 421 bp inayojumuisha tovuti lengwa ilitengenezwa kwa kutumia jozi ya primer (5′-ctccacctcacccttttaattg-3′ na 5′-caacttggaattctgatctttgc-3′), kusafishwa na kufanyiwa T7E1 kama ilivyoelezwa hapo awali, ambayo iliacha bendi za 228 bp na 193 bp zilizokatwa, mtawalia na/au kutumwa kwa upimaji wa Sanger ili kutathmini usambazaji wa indels unaozunguka tovuti iliyokatwa kwa uchambuzi wa ICE. Data yetu ilionyesha hakuna mlolongo wa aina ya mwitu uliobaki katika sampuli zilizohaririwa ikilinganishwa na zisizohaririwa. Hata hivyo, kuonyesha ufanisi wa uhariri wa 100% haikuwezekana kulingana na mwongozo wa uchambuzi wa ICE. Hasa, uchambuzi wa ICE unategemea sana ubora wa matokeo ya upimaji wa Sanger, hivyo jumla ya michango yote ya indel ni sawa na thamani ya R2 na mlolongo uliobaki unafafanuliwa kama sehemu isiyoeleweka. Tathmini ya kina ya alleles zilizovurugwa ilifanywa kwa kutumia upimaji wa kizazi kijacho wa amplicon inayolengwa (NGS) kwa kutumia jozi ya primer inayozunguka tovuti lengwa ya
     <italic>
      KLRC1
     </italic>
     (5′-acctgaatctgcccccaaac-3′ na 5′-ccaagctgcacatcctagac-3′)
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      <xref ref-type="bibr" rid="CR58">
       58
      </xref>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     . Usomaji wa mwisho wa jozi ulifanyiwa uchambuzi kwa kutumia toleo la mstari wa amri la CRISPResso2.
    </p>
   </sec>
   <sec id="Sec19">
    <title>
     Uchambuzi wa mtiririko wa seli
    </title>
    <p id="Par37">
     Uonyeshaji wa CD33-CAR na NKG2A kwenye seli za NK zilizobadilishwa jeni pamoja na uwezekano wa uchafuzi na seli zenye CD3-positivu ulifanyiwa uchambuzi kila siku 3-7 baada ya uhamisho kwa kutumia flow cytometry kwa kutumia mkakati wa gating kama inavyoonyeshwa katika Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S1a
     </xref>
     <sup/>
     . Uonyeshaji wa CD33-CAR ulifanyiwa uchambuzi kwa kuongeza protini ya CD33 iliyounganishwa na biotin na kuongeza ya pili ya kingamwili ya anti-biotin-PE (clone REA746; Miltenyi Biotec). Uonyeshaji wa uso wa seli wa NKG2A ulifanyiwa uchambuzi kwa kutumia kingamwili ya anti-NKG2A-PE (Clone Z199; Beckman Coulter). Ili kugundua uchafuzi wa seli zenye CD3-positivu kingamwili ya anti-CD3-BUV395 (clone SK7, BD Biosciences) ilitumika. Uonyeshaji wa uso wa seli wa CD94 ulifanyiwa uchambuzi kwa kutumia kingamwili ya anti-CD94-FITC (Clone REA113, Miltenyi Biotec). Itifaki ya phenotyping ilichapishwa hapo awali (kwa mkakati wa gating angalia Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      S4e
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     . Tazama orodha kamili ya kingamwili zote katika Jedwali la Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec20">
    <title>
     Jaribio la utendaji la seli za CAR-NK
    </title>
    <p id="Par38">
     Uharibifu wa seli kwa mwisho wa saa 4 au 24 za ushirikiano uliochochewa na seli za NK zisizobadilishwa (NT),
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ulitathminiwa kwa kutumia flow cytometry. Kwa hivyo, seli lengwa ama zilizo na GFP au zilizo na alama ya Cell Trace CFSE proliferation kit (Invitrogen) ziliunganishwa na seli za athari katika uwiano tofauti wa athari-lengwa (E:T) kwa muda uliowekwa katika 37 °C na 5% CO
     <sub>
      2
     </sub>
     <sup/>
     . Baadaye, seli zilitiwa rangi na 4’,6-Diamidino-2-phenylindole (DAPI) (AppliChem) na uhai wa seli lengwa ulitathminiwa kwa kutumia BD FACSCelesta (BD Biosciences). Ili kuchambua uharibifu wa seli kwa wakati halisi, mfumo wa picha za seli hai wa IncuCyte S3 (Sartorius) ulitumiwa kulingana na Mwongozo wa Bidhaa wa Incucyte Annexin V Dye. Sahani ya chini ya kisima 96 ilipakwa awali na 5 µg/ml fibronectin (Sigma-Aldrich) iliyoyeyushwa katika 0.1% BSA. Ili kuona apoptosis katika video, IncuCyte Annexin V Red Dye (Sartorius) iliongezwa kwenye media yenye 1 mM CaCl
     <sub>
      2
     </sub>
     kwa mkusanyiko wa mwisho wa 2.5 µM. Seli za GFP OCI-AML2 ziliunganishwa na seli za athari katika uwiano wa E:T wa 0.5:1, 1:1 au 2.5:1. Picha zilipatikana kila dakika 30 kwa kukuza mara 10
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     Safu ya chembe za cytometric
    </title>
    <p id="Par39">
     Utoaji wa cytokine wa seli za NT-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilizounganishwa na mistari ya seli za AML au seli za msingi za AML, pamoja na viwango vya cytokine katika damu kutoka kwa panya tofauti za NSG-SGM3 zilizotibiwa na seli za NK ulitambuliwa kwa kutumia BD Cytometric Bead Array (CBA; BD Biosciences) kama ilivyoelezwa awali
     <sup>
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     Maandalizi ya seli kwa uchambuzi wa qPCR na western blot
    </title>
    <p id="Par40">
     Seli za NT-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK ziliunganishwa na seli za OCI-AML2 katika uwiano wa E:T wa 3:1 kwa saa 2 katika medium ya NK-MACS iliyoongezwa na 5% plasma ya binadamu, 1% NK-MACS Supplements, 1% Pen/Strep na 500 U/ml IL-2 (Miltenyi Biotec au Novartis). Baadaye, seli zilitiwa rangi na 7-AAD (BD Biosciences) na kuchambuliwa kwa kutumia kifaa cha BD FACSAria Fusion (BD Biosciences). Seli za NK ziliwekwa kwenye GFP/7-AAD na seli za OCI-AML2 kwenye GFP/7-AAD
     <sup/>
     . Hatimaye, seli zilizungushwa kwa centrifuge, na pellets zilihifadhiwa kwenye -80 °C kwa uchambuzi zaidi wa qPCR au western blot. Kama udhibiti, seli za OCI-AML2 ziliunganishwa peke yake na kutoka kwa kila aina ya seli zilizungushwa kwa centrifuge, na pellets zilihifadhiwa kwenye -80 °C bila kuunganishwa.
    </p>
   </sec>
   <sec id="Sec23">
    <title>
     Upimaji wa jamaa wa mRNA
    </title>
    <p id="Par41">
     RNA ilitengwa kwa kutumia kifaa cha peqGOLD MicroSpin total RNA kulingana na mtengenezaji (PEQLAB Biotechnologie GmbH). Utengaji wa RNA ulijumuisha hatua ya digestion ya DNaseI kwenye safu (PEQLAB Biotechnologie GmbH). Uundaji wa cDNA ulifanywa kwa kutumia kifaa cha RevertAid first strand cDNA synthesis kit (ThermoFisher), kwa kutumia kiasi sawa cha 1 µg ya RNA kwa kila sampuli. qRT-PCR ilifanywa kwenye QuantStudio Flex 7 qRT-PCR cycler (Applied Biosystems) kwa kutumia Sybr Green PCR master mix (Applied Biosystmes). Kwa vichocheo vilivyotumika angalia Jedwali la Nyongeza
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     <sup/>
     . Upimaji wa kiasi cha jamaa wa nakala za RNA ulifanywa kwa kutumia njia ya ΔΔCq kama ilivyoelezwa mahali pengine
     <sup>
      <xref ref-type="bibr" rid="CR59">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="CR60">
       60
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec24">
    <title>
     Western blot
    </title>
    <p id="Par42">
     Utambuzi wa viwango vya usemi wa protini ulifanywa katika lysates za seli nzima, zilizoyeyushwa katika buffer ya Triton-X (30 mM Tris pH [7.4], 150 mM NaCl, 1% Triton-X, 10% glycerol, 0.5 mM PMSF, 2 mM DTT, 1x protease inhibitor cocktail (Roche)). Kingamwili zifuatazo zilitumika kwa utambuzi wa Western blot: sungura anti-Caspase-3 (Cell Signaling, 9662S), panya anti-Caspase-8 (Enzo, ADI-AAM-118-E), panya anti-PARP (poly(ADD)ribose polymerase) (Cell Signaling, 9546S), panya anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) (BioTrend, 5G4-6C5), sungura anti-Caspase-9 (Cell Signaling, 9502S), mbuzi anti-panya (Abcam, ab6789), mbuzi anti-sungura (Abcam, ab6721). Kingamwili za sekondari zilizounganishwa na horseradish peroxidase, na ishara ilipatikana kwa kutumia substrate ya kugundua chemiluminescence iliyoboreshwa (ThermoFisher). Angalia orodha kamili ya kingamwili zote katika Jedwali la Nyongeza
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     Maandalizi ya seli kwa uchambuzi wa CITE-seq
    </title>
    <p id="Par43">
     Kwa uchambuzi wa mpangilio wa seli moja, seli za NK zilizohifadhiwa (zilizobadilishwa kijenetiki) kutoka kwa wafadhili watatu tofauti zilifutwa na kupandikizwa kwa 2 × 10 seli/ml kwenye sahani ya visima 48 katika 750 µl kwenye kati ya NK-MACS iliyoongezwa na 1% ya Viongeza vya NK-MACS, 5% ya plasma ya binadamu, 1% Pen/Strep, 500 U/ml IL-2 (Miltenyi Biotec au Novartis) pamoja na 50 ng/ml IL-15 (CellGenix) kwa kila kisima. Siku tatu baadaye seli zilivunwa na kuunganishwa na seli za OCI-AML2 kwenye sahani za 6 cm kwa uwiano wa E:T wa 1:1. Seli za OCI-AML2 zilikuwa zimepakwa rangi awali na kifaa cha kuzalisha cha Cell Trace CFSE (Invitrogen) kulingana na itifaki ya mtengenezaji. Kama udhibiti, seli za NK zilipandwa bila kuwasiliana na seli za AML. Baada ya masaa 2 seli zilizopandwa zilivunwa, na kizuizi cha Fc kilifanywa kwa kutumia kingamwili za hIgG (Kiovig na Intratect, Hospitali ya Chuo Kikuu cha Frankfurt). Baadaye, seli zilipakwa rangi na kingamwili ya anti-NKG2A-PE (Clone Z199, Beckman Coulter), reagent ya kugundua CD33-CAR (CD33-protein-biotin + anti-biotin-APC (Clone RE746, Miltenyi Biotec) kulingana na aina ya seli na kila hali ilipakwa lebo na SampleTag tofauti kutoka kwa Kit ya Uchanganyaji wa Sampuli ya Seli Moja ya Binadamu (BD Biosciences). Baadaye, seli zilipakwa rangi na 7-AAD (BD Biosciences) ili kuondoa seli zilizokufa na zilisortiwa kwa kutumia mashine ya BD FACSAria. Seli za NK zilisortiwa kama ifuatavyo: NT-NK kama CFSE,
     <italic>
      KLRC1
     </italic>
     -NK kama CFSE/NKG2A, CAR33-NK kama CFSE/CAR na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK seli kama CFSE/NKG2A/CAR seli. Baadaye, mpangilio wa seli moja ulifanywa kwa kutumia mfumo wa uchambuzi wa Seli Moja wa BD Rhapsody (BD Biosciences)
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec26">
    <title>
     Uorodheshaji wa seli moja wa transcriptomes na epitopes kwa upimaji (CITE-Seq)
    </title>
    <p id="Par44">
     Kwa uchambuzi wa seli moja wa transcriptomes na epitopes, seli zilizopangwa ziliwekwa pamoja kwenye bomba la FACS la 5 ml, ili kuchambua idadi sawa ya seli kutoka kwa kila mfadhili na kila hali. Seli zilioshwa mara moja na kisha kusimamishwa tena katika 100 µL ya Stain Buffer (BSA) (BD Biosciences, cat# 554657). Kisha, seli ziliwekwa na mchanganyiko mkuu unao na 2 μL ya kila moja ya kingamwili 49 za BD AbSeq zilizounganishwa na oligonucleotide (BD Biosciences; angalia Jedwali la Nyongeza
     <xref ref-type="supplementary-material" rid="MOESM1">
      4
     </xref>
     ) kwa dakika 40 kwenye barafu. Baada ya kuoshwa mara mbili na BD Stain Buffer, seli zilisimamishwa tena katika 620 μL ya BD sample buffer (BD Biosciences, cartridge reagent kit, cat# 633731). Seli zilizosimamishwa zilipakwa rangi na 3.1 μL ya 2 mM Calcein AM (BD Biosciences, cat# 564061) na 3.1 μL ya Draq7 (BD Biosciences, cat# 564904) kwa dakika 5 katika 37 °C gizani. Mkazo wa seli na uhai ulitathminiwa kwa kutumia 10 µL ya seli zilizosimamishwa zilizopakwa rangi katika hemocytometer inayoweza kutupwa (Incyto, cat# DHC-N01-5) na BD Rhapsody Scanner. Seli zilizosimamishwa zenye seli 40,000 zilizokamatwa ziliandaliwa na kupakiwa mara moja kwenye cartridge ya BD Rhapsody (BD Biosciences, cat# 633733) kulingana na itifaki ya mtengenezaji. Chembe za kukamata zilizo na lebo ya oligonucleotide zilipakiwa kwenye cartridge na seli zilivunjwa na buffer ya kuvunja yenye 5 mM DTT. Chembe zinazokamata mRNA, Sample Tags na kingamwili zilizo na lebo ya oligonucleotide zilipatikana na kuwekwa pamoja kabla ya kutekelezwa kwa uandikishaji wa nyuma na matibabu ya exonuclease I (BD Biosciences, cDNA kit, cat# 633773). Maktaba za DNA ziliandaliwa kwa kutumia BD Rhapsody targeted mRNA na AbSeq amplification kit (BD Biosciences, cat# 633774). Kwa hivyo, Paneli ya Kujibu Kinga ya Binadamu iliyoundwa awali (BD Biosciences, cat# 633750) ilitumiwa pamoja na paneli ya primer iliyoundwa maalum ili kuongeza cDNA ya jeni 434 tofauti (angalia Jedwali la Nyongeza
     <xref ref-type="supplementary-material" rid="MOESM1">
      5
     </xref>
     ) kulingana na itifaki ya mtengenezaji. Mkazo na ukubwa wa maktaba za mwisho zenye faharasa za mpangilio wa Illumina zilichambuliwa kupitia Qubit 4 Fluorometer na kifaa cha High Sensitivity dsDNA kit (ThermoFisher Scientific, cat# Q32851) na Agilent 4150 Tapestation na kifaa cha High Sensitivity D1000 screentape (Agilent, cat# 5067-5584, 5067-5585). Maktaba kisha ziliwekwa pamoja kwa mkazo wa mwisho wa 1 nM na kupangwa pamoja na 20 % ya DNA ya PhiX katika mizunguko mingi (75 bp paired-end) kwenye mpangilio wa NextSeq2000 (Illumina).
    </p>
   </sec>
   <sec id="Sec27">
    <title>
     Uchambuzi wa data ya Uorodheshaji wa seli moja wa transcriptomes na epitopes kwa upimaji (CITE-Seq)
    </title>
    <p id="Par45">
     Faili za FASTQ zilizotengenezwa zilipakiwa pamoja na mfuatano wa marejeleo ya paneli kwa mRNAs na AbSeqs kwenye jukwaa la SevenBridges (Seven Bridges Genomics,
     <ext-link ext-link-type="uri" href="https://www.sevenbridges.com">
      https://www.sevenbridges.com
     </ext-link>
     ) na kuchakatwa kwa kutumia mfumo wa uchambuzi wa BD Rhapsody (BD Biosciences) na mipangilio ya msingi. Hivyo, jozi za usomaji wa ubora wa chini ziliondolewa na usomaji wa R1 uliobaki uliwekwa alama na msimbo wa upau wa seli na kitambulisho cha kipekee cha molekuli (UMI)s. Usomaji wa R2 kisha ulilinganishwa na mfuatano wa marejeleo ya maandiko na usomaji wenye lebo ya seli sawa, mfuatano wa UMI na jeni la marejeleo ziliunganishwa kuwa molekuli moja. Baadaye, algorithimu ya kurekebisha makosa ya uingizwaji wa kurudia (RSEC) ilitumika kurekebisha hesabu za molekuli kwa makosa ya mpangilio. Hatimaye, hesabu za seli zilipimwa, na Sample Tags zilipewa seli ili kuzalisha hesabu za molekuli zilizorekebishwa za RSEC.
    </p>
   </sec>
   <sec id="Sec28">
    <title>
     Muundo wa data ya ingizo
    </title>
    <p id="Par46">
     Hesabu za molekuli zilizorekebishwa za RSEC za wafadhili D1 na D2 ziligawanywa katika seli mbili x hesabu za vipengele, moja kwa ajili ya usemi wa jeni (RNA) na nyingine kwa ajili ya usemi wa alama za uso (alama zinazotokana na kingamwili, ADT). Kwa jumla, seli 60,957 zilitumika kwa uchambuzi (angalia Jedwali la Nyongeza
     <xref ref-type="supplementary-material" rid="MOESM1">
      6
     </xref>
     kwa muhtasari wa matokeo ya jukwaa la Seven Bridges Genomics).
    </p>
   </sec>
   <sec id="Sec29">
    <title>
     Mtiririko wa awali wa usindikaji
    </title>
    <p id="Par47">
     Tulichakata data kwa kuchunguza vipimo vya udhibiti wa ubora (QC) na kuchuja seli kulingana na vigezo vilivyobainishwa na mtumiaji, kwa kufuata mapendekezo ya Tomislav Ilicic et al. (2016)
     <sup>
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     . Tuliondoa seli zilizotajwa kama
     <italic>
      multiplets
     </italic>
     au
     <italic>
      undetermined
     </italic>
     na jukwaa la Seven Bridges Genomics. Zaidi ya hayo, tulitumia
     <italic>
      scater
     </italic>
     kuondoa vipimo vya nje kulingana na ukubwa wa maktaba na idadi ya vipengele vilivyogunduliwa. Baada ya kuchakata awali, seli 32,908 na 20,197 kutoka D1 na D2 zilibaki. Hatimaye, hesabu za RNA zilinormalishwa na kubadilishwa kwa njia ya logi kwa kutumia
     <italic>
      logNormCounts
     </italic>
     na hesabu za ADT zilinormalishwa kwa kutumia njia ya uwiano wa logi iliyowekwa katikati (CLR), iliyohesabiwa kwa uhuru kwa kila kipengele
     <sup>
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="CR62">
       62
      </xref>
      <xref ref-type="bibr" rid="CR61">
       61
      </xref>
      ,
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      <xref ref-type="bibr" rid="CR63">
       63
      </xref>
      ,
      <xref ref-type="bibr" rid="CR64">
       64
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec30">
    <title>
     Kusoma athari za CAR33 na
     <italic>
      KLRC1
     </italic>
     -KO kwenye seli za NK kwenye usemi wa alama za uso na transcript kabla ya ushirikiano na seli za AML
    </title>
    <sec id="Sec31">
     <title>
      Uchambuzi wa usemi wa jeni tofauti
     </title>
     <p id="Par48">
      Usindikaji wa data kwenye seti mbili za data zilizojumuishwa za wafadhili D1 na D2 ulifanywa kando kwenye meza za kuhesabu RNA na ADT. Tulitumia mbinu ya pseudo-bulk, ambapo tulijumlisha hesabu za vipengele katika makundi ya seli kulingana na hali (seli za NT-NK,
      <italic>
       KLRC1
      </italic>
      -NK, CAR33-NK na CAR33-
      <italic>
       KLRC1
      </italic>
      -NK) na wafadhili (D1 na D2). Kwa uchambuzi wa utofauti wa usemi wa RNA na vipengele vya ADT, tulitumia
      <italic>
       edgeR
      </italic>
      na
      <italic>
       limma
      </italic>
      , mtawalia
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      .
     </p>
     <p id="Par49">
      Tulibuni matrix ya mfano kulingana na vigezo tofauti vinavyohusika (kutumia fomula ya muundo: ~donor + CAR + KO + CAR:KO). Kwa RNA, tulifaa mfano wa log-linear wa binomial hasi ya uwezekano wa karibu kwa data ya kuhesabu, na tukajaribu utofauti wa usemi wa nakala kulingana na kizingiti maalum cha mabadiliko ya kukunja (=log2(1.2)) kwa kutumia
      <italic>
       glmQLFit
      </italic>
      na
      <italic>
       glmTreat
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
      </sup>
      . Kwa ADT, tulibadilisha data ya kuhesabu kuwa log2-hesabu kwa milioni (logCPM) kwa kutumia
      <italic>
       voom
      </italic>
      , na tukafaa mfano wa mstari kwa kila kipengele kwa kutumia
      <italic>
       lmFit
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Baada ya hapo, mbinu ya Bayes ya majaribio na kazi ya
      <italic>
       treat
      </italic>
      zilitumika kujaribu utofauti wa usemi wa alama za uso kulingana na kizingiti cha mabadiliko ya kukunja ya log2 (1.05)
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
      </sup>
      . Hatimaye, kwa utofauti uliotolewa, vipengele vya RNA na ADT viliorodheshwa kwa thamani ya
      <italic>
       p
      </italic>
      au mabadiliko ya kukunja ya logi (logFC) na kuainishwa kama vilivyopandishwa au kushushwa kwa kutumia
      <italic>
       decideTests
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Tuliripoti matokeo yetu katika michoro ya volcano (
      <italic>
       ggplot2
      </italic>
      ) na michoro ya nukta (
      <italic>
       scater
      </italic>
      ) huku tukionyesha vipengele maalum vya kuvutia
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec32">
     <title>
      Uchambuzi wa seli moja
     </title>
     <p id="Par50">
      Baada ya kusoma athari ya jumla ya kila moja ya hali tatu kwenye kiwango cha pseudo-bulk, pia tulifanya uchambuzi wa kina zaidi kwenye seli kabla ya utamaduni wa pamoja kwenye kiwango cha seli moja. Wafadhili wawili D1 na D2 walichambuliwa kando.
     </p>
    </sec>
    <sec id="Sec33">
     <title>
      Usindikaji wa data na ugawaji
     </title>
     <p id="Par51">
      Hesabu za vipengele vya ADT na RNA zilizowekwa kawaida zilijumuishwa katika matrix moja ya vipengele. Uchambuzi wa vipengele vya msingi (PCA) ulifanywa na vipengele 20 kabla ya kuunganisha kwa Louvain
      <sup>
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
      </sup>
      . Thamani tofauti za kigezo
      <italic>
       k
      </italic>
      , kinachowakilisha idadi ya majirani, zilijaribiwa na kutathminiwa kwa kutumia alama za kufanana za kuunganisha (kiwango kilichorekebishwa cha rand (ARI) &amp; kiwango cha rand kilichopimwa (WRI)). Matokeo ya kuunganisha kwa Louvain na
      <italic>
       k
      </italic>
      = 50 yalirudisha idadi inayofaa ya makundi na kupata alama ya juu zaidi katika alama zote za kufanana (Supplementary Fig.
      <xref ref-type="supplementary-material" rid="MOESM1">
       S3c
      </xref>
      ) na ilitumika katika uchambuzi wa mchakato wa chini. Matokeo yalionyeshwa kwenye t-distributed stochastic neighbor embedding (t-SNE)
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      .
     </p>
    </sec>
   </sec>
   <sec id="Sec34">
    <title>
     Kusoma athari za ushirikiano kwenye usemi wa alama za uso na transcript baada ya ushirikiano na AML
    </title>
    <p id="Par52">
     Baada ya kusoma athari za
     <italic>
      KLRC1
     </italic>
     , CAR33 na mwingiliano wao pamoja, tulitaka kuelewa mabadiliko ya usemi wa jeni na alama za uso baada ya utamaduni wa pamoja wa AML. Tulijumuisha seti zote mbili za data kutoka D1 na D2 bila kugawanya seli kulingana na utamaduni wa pamoja wa AML. Hii ilituruhusu kulinganisha seli kabla ya utamaduni wa pamoja na zile baada ya. Kwa jumla, tulikuwa na seli 53,105, ambapo 29,607 zilikuwa zimekuzwa pamoja na seli za AML. Tulitumia mbinu ya pseudo-bulk, ambapo tulijumlisha hesabu za vipengele katika makundi ya seli kulingana na kabla/baada ya utamaduni wa pamoja, hali (seli za NT-NK,
     <italic>
      KLRC1
     </italic>
     -NK, CAR33-NK na CAR33-
     <italic>
      KLRC1
     </italic>
     -NK) na wafadhili (D1 na D2)
     <sup/>
     .
    </p>
    <sec id="Sec35">
     <title>
      Usemi wa jeni tofauti
     </title>
     <p id="Par53">
      Tulibuni matrixi yetu ya mfano kwa tofauti mbalimbali kwa kutumia fomula ya muundo: ~ coculture + CAR + KO + CAR:KO. Kuanzia hapa, utaratibu ule ule ulioelezwa katika sehemu ya mbinu "Kusoma athari za CAR33 na KLRC1-KO kwenye seli za NK" ulitumika. Zaidi ya hayo, tulitumia kazi ya
      <italic>
       scran
      </italic>
      ya
      <italic>
       find Markers
      </italic>
      kusoma vipengele vilivyoonyeshwa tofauti katika kila hali baada ya coculture. Tulihesabu thamani za logFC za vipengele vya RNA na ADT kwa kila hali baada ya coculture ikilinganishwa na hali ile ile kabla ya coculture. Hii ilituruhusu kusoma athari za coculture kwenye hali za kibinafsi, badala ya athari ya jumla inayoonyeshwa katika michoro ya awali. Matokeo yalionyeshwa katika ramani ya joto
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
      </sup>
      <sup/>
      .
     </p>
    </sec>
    <sec id="Sec36">
     <title>
      Uchambuzi wa seli moja
     </title>
     <p id="Par54">
      Baada ya kuelewa athari ya jumla ya coculture katika kiwango cha pseudo-bulk, tulitaka kusoma hiyo katika kiwango cha seli moja. Tofauti na uchambuzi wetu wa pseudo-bulk, tulilenga kwenye seli baada ya coculture katika uchambuzi wetu wa seli moja na tulisoma wafadhili wote D1 na D2 kando ili kuepuka masuala ya kundi. Hii ilijumuisha seli 18,604 na 11,003 kutoka D1 na D2, mtawalia.
     </p>
    </sec>
    <sec id="Sec37">
     <title>
      Usindikaji wa data
     </title>
     <p id="Par55">
      Sawa na uchambuzi wa awali wa seli moja, PCA ilihesabiwa na vipengele 20 na clustering ya Louvain ilifanywa kwenye maadili ya ADT na RNA yaliyofungamana kwa kutumia
      <italic>
       scran
      </italic>
      na
      <italic>
       k
      </italic>
      = 50, na
      <italic>
       igraph
      </italic>
      <sup/>
      . Matokeo yalionyeshwa kwenye ramani ya t-SNE. Alama mbalimbali za muhtasari kwa vipengele vya alama zinazowezekana kutofautisha kati ya makundi zilihesabiwa kwa kutumia
      <italic>
       scoreMarkers
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
       ,
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      . Thamani za maonyesho ya vipengele vya juu kulingana na wastani wa Eneo Chini ya Mstari (AUC) wa kundi la maslahi zinaonyeshwa katika mchoro wa nukta katika makundi yote.
     </p>
    </sec>
   </sec>
   <sec id="Sec38">
    <title>
     Utafiti wa utendaji wa in vivo wa seli za CAR33-
     <italic>
      KLRC1
     </italic>
     <sup>
      ko
     </sup>
     -NK katika panya walio na xenograft
    </title>
    <p id="Par56">
     Panya wa NOD.Cg-
     <italic>
      Prkdc
     </italic>
     <italic>
      Il2rg
     </italic>
     Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (NSG-SGM3) walipatikana kutoka
     <italic>
      The Jackson Laboratory
     </italic>
     , Bar Harbor, ME, USA (JAX stock No.: #013062 (NSG-SGM3)
     <sup>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     . Panya walihifadhiwa chini ya hali maalum za SPF zenye upatikanaji wa kutosha wa chakula na maji na wanyama wa majaribio/kudhibiti waliowekwa pamoja. Kwa mfano wa panya wa OCI-AML2-xenograft, seli 0.5×10 za OCI-AML2 (GFP, Luc) zilidungwa kupitia mshipa wa mkia kwenye panya wa NSG-SGM3 (≤wiki 15, dume). Katika siku ya pili/tatu baada ya matumizi ya seli za AML, upandikizaji wa seli za leukemiki ulitathminiwa kwa kudunga luciferin chini ya ngozi na kuchambua ishara ya bioluminescence kwa kutumia Mfumo wa Upigaji Picha wa IVIS Lumina II Multispectral (PerkinElmer). Katika siku ya tatu na/au saba na siku ya kumi seli 5 × 10 au 3 × 10 za NT-,
     <italic>
      KLRC1
     </italic>
     -, CAR33- au CAR33-
     <italic>
      KLRC1
     </italic>
     -NK zilitolewa kupitia mshipa wa mkia huku kundi moja la panya halikupokea matibabu yoyote. Seli za NK zilipatikana kutoka kwa mfadhili yule yule na zilikuwa zimekuzwa kwa siku 18 baada ya nucleofection wakati wa sindano ya kwanza na siku 25 baada ya nucleofection wakati wa sindano inayofuata. Zaidi ya hayo, siku ya sindano ya seli za NK sindano ya kila siku ya chini ya ngozi ya 25,000 IU IL-2 (Novartis) ilianza kwa panya waliopokea seli za NK. Muonekano, tabia na uzito wa wanyama ulifuatiliwa kila siku 2-3 na mzigo wa leukemiki ulitathminiwa kupitia BLI, euthanasia ilifanywa kupitia dislocation ya kizazi chini ya anesthesia ya kuvuta pumzi ya isoflurane. Katika siku ya 17 panya walitolewa kafara au walienda kwa ajili ya kuishi. Kwa uchambuzi wa re-engraftment ya BM seli za BM zilitengwa kutoka kwa kila panya na kuwekwa katika RPMI1640 na Glutamax, +10% FCS, +1% P/S hadi sindano ya i.v. Seli za BM kutoka kila kundi la matibabu zilipooliwa na seli 5 × 10 zilidungwa ndani ya mishipa kwenye panya wa NSG-SGM3 (≤wiki 16, dume/jike). Panya walipimwa uzito na alama mara kwa mara na uchambuzi wa BLI ulifanywa mara moja kwa wiki kugundua ukuaji wa Leukemiki. Panya waliuawa wakati maadili ya BLI yalizidi (wakati wa kufichua kamera ya ~60,000 hesabu), au vigezo vya utoaji mimba vilipofikiwa (kupoteza uzito kwa zaidi ya 20% ya uzito wa kawaida, dalili kama: apathy, athari za kujihami zinazoonekana, kupungua kwa turgor ya ngozi, shida za kupumua zinazoonekana, kuhara kali, matatizo ya motor (mfano, kupepesa, harakati za kulazimisha), au mkao usio wa kawaida, usio wa kawaida wa mwili (mfano, mkao wa kuinama, opisthotonus). Majaribio yote yaliidhinishwa na Regierungspräsidium Darmstadt, Ujerumani
     <sup/>
     .
    </p>
   </sec>
   <sec id="Sec39">
    <title>
     Uchambuzi wa takwimu
    </title>
    <p id="Par57">
     Kwa uchambuzi wa takwimu, usambazaji wa kawaida wa utendaji wa seli za NK ulidhaniwa kutokana na utumiaji wa wafadhili wenye afya kama chanzo cha seli za NK. Kuhusu majaribio ya panya in vivo pia usambazaji wa kawaida unaweza kudhaniwa. Uchambuzi wa takwimu ulifanywa kwa kutumia GraphPad PRISM toleo la 6–9 (GraphPad Software, Inc.) kwa majaribio yenye wafadhili/wanyama watatu au zaidi.
    </p>
   </sec>
   <sec id="Sec40">
    <title>
     Muhtasari wa kuripoti
    </title>
    <p id="Par58">
     Maelezo zaidi juu ya muundo wa utafiti yanapatikana katika
     <xref ref-type="supplementary-material" rid="MOESM9">
      Muhtasari wa Kuripoti wa Nature Portfolio
     </xref>
     uliounganishwa na makala hii.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Shukrani
   </title>
   <p>
    Waandishi wanawashukuru wagonjwa wote waliochangia kwenye utafiti kwa kutoa sampuli za leukapheresis. Waandishi wanamshukuru Ralf Schubert kwa msaada na uchambuzi wa CBA, na Petra Dinse, Petra Schoen, Bernd Lecher, Simone Maurer, Beate vom Hövel, Daniela Brücher, Katja Stein, Franziska Ganß kwa msaada wao bora wa kiufundi, Lea Knapp kwa msaada wa majaribio, Sarah Mertlitz kwa msaada katika kuunda picha za hadubini ya confocal, na wanachama wa timu kutoka kituo cha wanyama cha GSH na jukwaa la ufuatiliaji wa kinga la FCI kwa msaada wa majaribio, na Christian Brandts kwa msaada na UCT Biobank kutoa sampuli za AML. Tunamshukuru Lisa Marie Reindl kwa majadiliano yenye msaada. Zaidi ya hayo, tunawashukuru washirika wa ushirikiano wa viwanda kutoka BD Bioscience, Sartorius, PerkinElmer, Revvity na Miltenyi Biotec kwa msaada bora katika matumizi ya kiufundi. Kazi hii iliungwa mkono na Stiftung Deutsche Krebshilfe (Msaada wa Saratani ya Ujerumani) katika miradi ya kibinafsi (#70114124 kwa E.U., M.V.) katika mpango wa Oncology ya Tafsiri (#70114180 kwa N.A., E.U.) na wa "CAR FACTORY" (#70115200 kwa E.U., T. Ca.), na Deutsche Forschungsgemeinschaft (DFG, Shirika la Utafiti la Ujerumani) katika mpango wa SFB/IRTG 1292 (Project-ID 318346496 kwa E.U., N.A., L.B.) na miradi ya kibinafsi RI 2462/9-1 na RI 2462/10-1 (kwa M.A.R), na CA 311/7-1 (kwa T.Ca.), na Jose Carreras Leukemia Foundation (kwa E.U., O.P., M.A.R. na DJCLS 11R/2020, 23R/2021 na DJCLS 15R/2023), na Deutsche Kinderkrebsstiftung DKS_2023_01 (kwa M.V.), na msingi "Hilfe für krebskranke Kinder Frankfurt e.V." katika mpango wa C
    <sup>
     3
    </sup>
    OMBAT-AML consortium (kwa J.-H.K., R.B., E.U.); na na LOEWE Center Frankfurt Cancer Institute (FCI, Hessen State Ministry for Higher Education, Research and the Arts, III L 5 − 519/03/03.001). T.B. aliungwa mkono na DFG, INDEEP Clinician Scientist Program (Project-ID 493624332), T.B., K.I., S.W. na A.A. waliungwa mkono na MSNZ Frankfurt (Msaada wa Saratani ya Ujerumani), na H.M.R. na Wizara ya Elimu ya Juu ya Misri kwa kufadhili udhamini wa baada ya udaktari wa miezi sita katika kikundi cha utafiti kutoka O.P., Chuo Kikuu cha Charite Berlin, Ujerumani. Takwimu zimeundwa kwa kutumia leseni ya BioRender CC-BY (Figs.
    <xref ref-type="fig" rid="Fig1">
     1
    </xref>
    a,
    <xref ref-type="fig" rid="Fig2">
     2
    </xref>
    a,
    <xref ref-type="fig" rid="Fig5">
     5
    </xref>
    a
    <xref ref-type="fig" rid="Fig6">
     6a
    </xref>
    , sehemu katika Figs.
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    a,
    <xref ref-type="fig" rid="Fig7">
     7
    </xref>
    e,
    <xref ref-type="fig" rid="Fig7">
     7h
    </xref>
    , na Mchoro wa Ziada
    <xref ref-type="supplementary-material" rid="MOESM1">
     2a
    </xref>
    ).
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Mchango wa waandishi
   </title>
   <p>
    T.B., N.A., L.B., P.W., A.G., V.S., J.A. H.M.R., B.A.J. walifanya majaribio; A.G. alifanya usindikaji wa awali na A.A., K.I. walichambua data za CITE-seq. V.S., M.V. walichambua data za qPCR. S.W. alitoa data za kliniki. N.A., T.B., L.B. walichambua data zote nyingine. E.U., K.I., N.A., T.B. walibuni na kuelekeza utafiti; N.A., T.B., A.A., K.I. walifanya uchambuzi wa takwimu; E.U., K.I., R.B., T.O., J.-H.K., O.P., M.A.R., T.Ca.; N.M., M.V. walijadili matokeo pamoja na waandishi wenza wote. T.B., N.A., K.I., E.U. waliandika maandiko kwa mchango wa waandishi wenza wote.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Mapitio ya rika
   </title>
   <sec id="FPar1">
    <title>
     Taarifa ya mapitio ya rika
    </title>
    <p id="Par59">
     <italic>
      Nature Communications
     </italic>
     thanks May Daher, Naval Daver, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec>
   <title>
    Ufadhili
   </title>
   <p>
    Open Access funding enabled and organized by Projekt DEAL.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa data
   </title>
   <p>
    All sequencing data concerning CITE-seq experiments has been deposited in the NCBI GEO repository under accession number
    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221552">
     GSE221552
    </ext-link>
    .
    <xref ref-type="sec" rid="Sec42">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa msimbo
   </title>
   <p>
    All code used to analyze CITE-seq data is available in the following github repository:
    <ext-link ext-link-type="uri" xlink:href="https://github.com/AGImkeller/CD33_NK_cells_2022">
     https://github.com/AGImkeller/CD33_NK_cells_2022
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Maslahi yanayokinzana
    </title>
    <p id="Par60">
     E.U. has a sponsored research project with Gilead and BMS and acts as medical advisor of Phialogics and CRIION. T.O. has disclosures to Merck KGaA: Honoraria; Gilead: Research Funding; Merck KGaA: Research Funding; Roche: Honoraria. O.P. has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos, he has received research support from Gilead, Incyte, Jazz, Neovii Biotech, and Takeda and is member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. N.M. is employee of Miltenyi Biotec. T.B., P.W., E.U. have filed patents on data partly published in this manuscript: PCT/EP2024/060767: Treatment of leukemia with engineered immune checkpoint inactivated CAR-NK cells and CAR-T cells (U31175WO). No competing interests exists for the remaining authors.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Marejeleo
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Hartmann
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Ullrich
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
      </article-title>
      <source>
       Gene Ther.
      </source>
      <year>
       2021
      </year>
      <volume>
       28
      </volume>
      <fpage>
       513
      </fpage>
      <lpage>
       527
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXntVOrsL8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33753909
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8455322
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41434-021-00246-w
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maude
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2018
      </year>
      <volume>
       378
      </volume>
      <fpage>
       439
      </fpage>
      <lpage>
       448
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXitlylsLw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29385370
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5996391
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1709866
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Munshi
        </surname>
        <given-names>
         NC
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Idecabtagene vicleucel in relapsed and refractory multiple myeloma
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       384
      </volume>
      <fpage>
       705
      </fpage>
      <lpage>
       716
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXlt1KgsLY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33626253
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa2024850
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bouchkouj
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
      </article-title>
      <source>
       Oncologist
      </source>
      <year>
       2022
      </year>
      <volume>
       27
      </volume>
      <fpage>
       892
      </fpage>
      <lpage>
       899
      </lpage>
      <pub-id pub-id-type="pmid">
       35983953
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9526496
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/oncolo/oyac163
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Maude
        </surname>
        <given-names>
         SL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Chimeric antigen receptor T cells for sustained remissions in leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2014
      </year>
      <volume>
       371
      </volume>
      <fpage>
       1507
      </fpage>
      <lpage>
       1517
      </lpage>
      <pub-id pub-id-type="pmid">
       25317870
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4267531
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1407222
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Liu
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2020
      </year>
      <volume>
       382
      </volume>
      <fpage>
       545
      </fpage>
      <lpage>
       553
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXjtlCgtro%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32023374
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7101242
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1910607
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Marin
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2024
      </year>
      <volume>
       30
      </volume>
      <fpage>
       772
      </fpage>
      <lpage>
       784
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhvFantrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38238616
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10957466
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-023-02785-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Döhner
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <name>
        <surname>
         Weisdorf
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Bloomfield
        </surname>
        <given-names>
         CD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Acute myeloid leukemia
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2015
      </year>
      <volume>
       373
      </volume>
      <fpage>
       1136
      </fpage>
      <lpage>
       1152
      </lpage>
      <pub-id pub-id-type="pmid">
       26376137
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMra1406184
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Haubner
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
      </article-title>
      <source>
       Leukemia
      </source>
      <year>
       2019
      </year>
      <volume>
       33
      </volume>
      <fpage>
       64
      </fpage>
      <lpage>
       74
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BB3c%2FitFGqsA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       29946192
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41375-018-0180-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ehninger
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
      </article-title>
      <source>
       Blood Cancer J.
      </source>
      <year>
       2014
      </year>
      <volume>
       4
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC2cfis1yktA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       24927407
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4080210
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/bcj.2014.39
      </pub-id>
      <elocation-id>
       e218
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dutour
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia
      </article-title>
      <source>
       Adv. Hematol.
      </source>
      <year>
       2012
      </year>
      <volume>
       2012
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC387nt1WhtA%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       22272203
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3261457
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1155/2012/683065
      </pub-id>
      <elocation-id>
       683065
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kim
        </surname>
        <given-names>
         MY
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2018
      </year>
      <volume>
       173
      </volume>
      <fpage>
       1439
      </fpage>
      <lpage>
       1453.e19
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXhtVKntrfP
      </pub-id>
      <pub-id pub-id-type="pmid">
       29856956
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6003425
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2018.05.013
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Reindl
        </surname>
        <given-names>
         LM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Immunotherapy with NK cells: recent developments in gene modification open up new avenues
      </article-title>
      <source>
       Oncoimmunology
      </source>
      <year>
       2020
      </year>
      <volume>
       9
      </volume>
      <pub-id pub-id-type="pmid">
       33457093
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7781759
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1080/2162402X.2020.1777651
      </pub-id>
      <elocation-id>
       1777651
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Szczepanski
        </surname>
        <given-names>
         MJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors
      </article-title>
      <source>
       Cancer Immunol. Immunother.
      </source>
      <year>
       2010
      </year>
      <volume>
       59
      </volume>
      <fpage>
       73
      </fpage>
      <lpage>
       79
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXht1OnsL%2FO
      </pub-id>
      <pub-id pub-id-type="pmid">
       19526239
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00262-009-0724-5
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rubnitz
        </surname>
        <given-names>
         JE
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
      </article-title>
      <source>
       J. Clin. Oncol.
      </source>
      <year>
       2010
      </year>
      <volume>
       28
      </volume>
      <fpage>
       955
      </fpage>
      <lpage>
       959
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3cXktF2ltrw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20085940
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2834435
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1200/JCO.2009.24.4590
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Romee
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
      </article-title>
      <source>
       Sci. Transl. Med.
      </source>
      <year>
       2016
      </year>
      <volume>
       8
      </volume>
      <fpage>
       357ra123
      </fpage>
      <pub-id pub-id-type="pmid">
       27655849
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5436500
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/scitranslmed.aaf2341
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Miller
        </surname>
        <given-names>
         JS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2005
      </year>
      <volume>
       105
      </volume>
      <fpage>
       3051
      </fpage>
      <lpage>
       3057
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2MXjtlSmtb0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15632206
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood-2004-07-2974
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Paczulla
        </surname>
        <given-names>
         AM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2019
      </year>
      <volume>
       572
      </volume>
      <fpage>
       254
      </fpage>
      <lpage>
       259
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhtl2qsLvF
      </pub-id>
      <pub-id pub-id-type="pmid">
       31316209
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6934414
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41586-019-1410-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Blood Cancer J.
      </source>
      <year>
       2022
      </year>
      <volume>
       12
      </volume>
      <pub-id pub-id-type="pmid">
       35418180
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9007937
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41408-022-00660-2
      </pub-id>
      <elocation-id>
       61
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Albinger
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Bone Marrow Transpl.
      </source>
      <year>
       2024
      </year>
      <volume>
       59
      </volume>
      <fpage>
       489
      </fpage>
      <lpage>
       495
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhvFartb0%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41409-023-02180-4
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Braud
        </surname>
        <given-names>
         VM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
      </article-title>
      <source>
       Nature
      </source>
      <year>
       1998
      </year>
      <volume>
       391
      </volume>
      <fpage>
       795
      </fpage>
      <lpage>
       799
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       1998Natur.391..795B
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DyaK1cXhtlCjtbo%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       9486650
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/35869
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Le Dréan
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases
      </article-title>
      <source>
       Eur. J. Immunol.
      </source>
      <year>
       1998
      </year>
      <volume>
       28
      </volume>
      <fpage>
       264
      </fpage>
      <lpage>
       276
      </lpage>
      <pub-id pub-id-type="pmid">
       9485206
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1002/(SICI)1521-4141(199801)28:01&lt;264::AID-IMMU264&gt;3.0.CO;2-O
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         André
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells
      </article-title>
      <source>
       Cell
      </source>
      <year>
       2018
      </year>
      <volume>
       175
      </volume>
      <fpage>
       1731
      </fpage>
      <lpage>
       1743.e13
      </lpage>
      <pub-id pub-id-type="pmid">
       30503213
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6292840
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.cell.2018.10.014
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tognarelli
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Enhancing the activation and releasing the brakes: a double hit strategy to improve NK cell cytotoxicity against multiple myeloma
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2018
      </year>
      <volume>
       9
      </volume>
      <fpage>
       2743
      </fpage>
      <pub-id pub-id-type="pmid">
       30542346
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6277768
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2018.02743
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
      </article-title>
      <source>
       Oncoimmunology
      </source>
      <year>
       2022
      </year>
      <volume>
       11
      </volume>
      <pub-id pub-id-type="pmid">
       35694192
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9176243
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1080/2162402X.2022.2081415
      </pub-id>
      <elocation-id>
       2081415
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Reindl
        </surname>
        <given-names>
         LM
        </given-names>
       </name>
       <name>
        <surname>
         Ullrich
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Nonviral technologies can pave the way for CAR-NK cell therapy
      </article-title>
      <source>
       J. Leukoc. Biol.
      </source>
      <year>
       2023
      </year>
      <volume>
       114
      </volume>
      <fpage>
       475
      </fpage>
      <lpage>
       486
      </lpage>
      <pub-id pub-id-type="pmid">
       37403203
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/jleuko/qiad074
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Holling
        </surname>
        <given-names>
         TM
        </given-names>
       </name>
       <name>
        <surname>
         Schooten
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <name>
        <surname>
         van Den Elsen
        </surname>
        <given-names>
         PJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men
      </article-title>
      <source>
       Hum. Immunol.
      </source>
      <year>
       2004
      </year>
      <volume>
       65
      </volume>
      <fpage>
       282
      </fpage>
      <lpage>
       290
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2cXjs1Gitrc%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       15120183
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.humimm.2004.01.005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Post
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The transcription factor ZNF683/HOBIT regulates human NK-cell development
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2017
      </year>
      <volume>
       8
      </volume>
      <fpage>
       535
      </fpage>
      <pub-id pub-id-type="pmid">
       28555134
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5430038
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2017.00535
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Metkar
        </surname>
        <given-names>
         SS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis
      </article-title>
      <source>
       J. Cell Biol.
      </source>
      <year>
       2003
      </year>
      <volume>
       160
      </volume>
      <fpage>
       875
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXitlSltrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       12629051
      </pub-id>
      <pub-id pub-id-type="pmcid">
       2173758
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1083/jcb.200210158
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jayavelu
        </surname>
        <given-names>
         AK
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The proteogenomic subtypes of acute myeloid leukemia
      </article-title>
      <source>
       Cancer Cell
      </source>
      <year>
       2022
      </year>
      <volume>
       40
      </volume>
      <fpage>
       301
      </fpage>
      <lpage>
       317.e12
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XlvVekurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35245447
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ccell.2022.02.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="other">
      013062 - NSG-SGM3 Strain Details.
      <ext-link ext-link-type="uri" xlink:href="https://www.jax.org/strain/013062">
       https://www.jax.org/strain/013062#
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wunderlich
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
      </article-title>
      <source>
       Leukemia
      </source>
      <year>
       2010
      </year>
      <volume>
       24
      </volume>
      <fpage>
       1785
      </fpage>
      <lpage>
       1788
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC3cfovVWmug%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       20686503
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5439963
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/leu.2010.158
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rasheed
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
       <name>
        <surname>
         Donia
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
       <name>
        <surname>
         Nadwan
        </surname>
        <given-names>
         EA
        </given-names>
       </name>
       <name>
        <surname>
         Mourad
        </surname>
        <given-names>
         ZI
        </given-names>
       </name>
       <name>
        <surname>
         Farahat
        </surname>
        <given-names>
         N
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Identifying leukemia-associated immunophenotypes in acute myeloid leukemia patients using multiparameter flow cytometry
      </article-title>
      <source>
       Oman Med. J.
      </source>
      <year>
       2021
      </year>
      <volume>
       36
      </volume>
      <fpage>
       e323
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xht1SltL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       35024173
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8722324
      </pub-id>
      <pub-id pub-id-type="doi">
       10.5001/omj.2021.108
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Heuser
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2021
      </year>
      <volume>
       138
      </volume>
      <fpage>
       2753
      </fpage>
      <lpage>
       2767
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XislGqsg%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       34724563
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8718623
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2021013626
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ruggeri
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
      </article-title>
      <source>
       Science
      </source>
      <year>
       2002
      </year>
      <volume>
       295
      </volume>
      <fpage>
       2097
      </fpage>
      <lpage>
       2100
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2002Sci...295.2097R
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38Xit1Ohurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       11896281
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/science.1068440
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wendel
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy
      </article-title>
      <source>
       Cancers (Basel)
      </source>
      <year>
       2021
      </year>
      <volume>
       13
      </volume>
      <fpage>
       1481
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhslClsL3K
      </pub-id>
      <pub-id pub-id-type="pmid">
       33807011
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/cancers13061481
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR37">
     <label>
      37.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Cooley
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
      </article-title>
      <source>
       Blood Adv.
      </source>
      <year>
       2019
      </year>
      <volume>
       3
      </volume>
      <fpage>
       1970
      </fpage>
      <lpage>
       1980
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVKgsLjM
      </pub-id>
      <pub-id pub-id-type="pmid">
       31266741
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6616260
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/bloodadvances.2018028332
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR38">
     <label>
      38.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Crinier
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia
      </article-title>
      <source>
       Cell Mol. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       18
      </volume>
      <fpage>
       1290
      </fpage>
      <lpage>
       1304
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXisVWnt7jM
      </pub-id>
      <pub-id pub-id-type="pmid">
       33239726
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41423-020-00574-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR39">
     <label>
      39.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dufva
        </surname>
        <given-names>
         O
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers
      </article-title>
      <source>
       Immunity
      </source>
      <year>
       2023
      </year>
      <volume>
       56
      </volume>
      <fpage>
       2816
      </fpage>
      <lpage>
       2835.e13
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXis1WntLfF
      </pub-id>
      <pub-id pub-id-type="pmid">
       38091953
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.immuni.2023.11.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR40">
     <label>
      40.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schneider
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia
      </article-title>
      <source>
       Front. Oncol.
      </source>
      <year>
       2018
      </year>
      <volume>
       8
      </volume>
      <fpage>
       539
      </fpage>
      <pub-id pub-id-type="pmid">
       30524966
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6262782
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fonc.2018.00539
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR41">
     <label>
      41.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hejazi
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       CD33 delineates two functionally distinct NK cell populations divergent in cytokine production and antibody-mediated cellular cytotoxicity
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFels7nE
      </pub-id>
      <pub-id pub-id-type="pmid">
       35058934
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2021.798087
      </pub-id>
      <elocation-id>
       798087
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR42">
     <label>
      42.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hunt
        </surname>
        <given-names>
         JMT
        </given-names>
       </name>
       <name>
        <surname>
         Samson
        </surname>
        <given-names>
         CA
        </given-names>
       </name>
       <name>
        <surname>
         Rand
        </surname>
        <given-names>
         Adu
        </given-names>
       </name>
       <name>
        <surname>
         Sheppard
        </surname>
        <given-names>
         HM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells
      </article-title>
      <source>
       Hum. Genet.
      </source>
      <year>
       2023
      </year>
      <volume>
       142
      </volume>
      <fpage>
       705
      </fpage>
      <lpage>
       720
      </lpage>
      <pub-id pub-id-type="pmid">
       37093294
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10182114
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00439-023-02561-1
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR43">
     <label>
      43.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rad
        </surname>
        <given-names>
         SMAH
        </given-names>
       </name>
       <name>
        <surname>
         Poudel
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Tan
        </surname>
        <given-names>
         GMY
        </given-names>
       </name>
       <name>
        <surname>
         McLellan
        </surname>
        <given-names>
         AD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Promoter choice: Who should drive the CAR in T cells?
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2020
      </year>
      <volume>
       15
      </volume>
      <fpage>
       e0232915
      </fpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0232915
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR44">
     <label>
      44.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Klermund
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       On- and off-target effects of paired CRISPR-Cas nickase in primary human cells
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2024
      </year>
      <volume>
       32
      </volume>
      <fpage>
       1298
      </fpage>
      <lpage>
       1310
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXmtFGms7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38459694
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2024.03.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR45">
     <label>
      45.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Turchiano
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
      </article-title>
      <source>
       Cell Stem Cell
      </source>
      <year>
       2021
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1136
      </fpage>
      <lpage>
       1147.e5
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXltFOmurY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33626327
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.stem.2021.02.002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR46">
     <label>
      46.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nguyen
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
      </article-title>
      <source>
       Bone Marrow Transpl.
      </source>
      <year>
       2009
      </year>
      <volume>
       43
      </volume>
      <fpage>
       693
      </fpage>
      <lpage>
       699
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXlvVGrsL0%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/bmt.2008.380
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR47">
     <label>
      47.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Biederstädt
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Rezvani
        </surname>
        <given-names>
         K
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2023
      </year>
      <volume>
       141
      </volume>
      <fpage>
       22
      </fpage>
      <lpage>
       38
      </lpage>
      <pub-id pub-id-type="pmid">
       35512203
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2021012411
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR48">
     <label>
      48.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Majzner
        </surname>
        <given-names>
         RG
        </given-names>
       </name>
       <name>
        <surname>
         Mackall
        </surname>
        <given-names>
         CL
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Clinical lessons learned from the first leg of the CAR T cell journey
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2019
      </year>
      <volume>
       25
      </volume>
      <fpage>
       1341
      </fpage>
      <lpage>
       1355
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhslelurbN
      </pub-id>
      <pub-id pub-id-type="pmid">
       31501612
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41591-019-0564-6
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR49">
     <label>
      49.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Daher
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2021
      </year>
      <volume>
       137
      </volume>
      <fpage>
       624
      </fpage>
      <lpage>
       636
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXjvVemsb8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       32902645
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7869185
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2020007748
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR50">
     <label>
      50.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jo
        </surname>
        <given-names>
         D-H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles
      </article-title>
      <source>
       Mol. Ther. Methods Clin. Dev.
      </source>
      <year>
       2023
      </year>
      <volume>
       29
      </volume>
      <fpage>
       173
      </fpage>
      <lpage>
       184
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXmsFOgs7w%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       37063482
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10102412
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.omtm.2023.03.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR51">
     <label>
      51.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lupo
        </surname>
        <given-names>
         KB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2024
      </year>
      <volume>
       15
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2024NatCo..15.1909L
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXlsVKmsrg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       38429294
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10907695
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-024-46343-3
      </pub-id>
      <elocation-id>
       1909
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR52">
     <label>
      52.
     </label>
     <mixed-citation publication-type="other">
      Research, C. for B. E. and. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies.
      <italic>
       FDA
      </italic>
      (2023).
     </mixed-citation>
    </ref>
    <ref id="CR53">
     <label>
      53.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bexte
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors
      </article-title>
      <source>
       Mol. Ther.
      </source>
      <year>
       2024
      </year>
      <volume>
       32
      </volume>
      <fpage>
       2357
      </fpage>
      <lpage>
       2372
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXht1ajtbvJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       38751112
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ymthe.2024.05.022
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR54">
     <label>
      54.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kath
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells
      </article-title>
      <source>
       Blood
      </source>
      <year>
       2024
      </year>
      <volume>
       143
      </volume>
      <fpage>
       2599
      </fpage>
      <lpage>
       2611
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB2cXhtlOgtbnL
      </pub-id>
      <pub-id pub-id-type="pmid">
       38493479
      </pub-id>
      <pub-id pub-id-type="pmcid">
       11196866
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1182/blood.2023020973
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR55">
     <label>
      55.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Müller
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       3123
      </fpage>
      <pub-id pub-id-type="pmid">
       32117200
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.03123
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR56">
     <label>
      56.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Colamartino
        </surname>
        <given-names>
         ABL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       2873
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVCgtrbO
      </pub-id>
      <pub-id pub-id-type="pmid">
       31921138
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6927467
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.02873
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR57">
     <label>
      57.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bari
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2019
      </year>
      <volume>
       10
      </volume>
      <fpage>
       2001
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXks1Squ70%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       31507603
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6713925
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2019.02001
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR58">
     <label>
      58.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Alzubi
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Automated generation of gene-edited CAR T cells at clinical scale
      </article-title>
      <source>
       Mol. Ther. Methods Clin. Dev.
      </source>
      <year>
       2021
      </year>
      <volume>
       20
      </volume>
      <fpage>
       379
      </fpage>
      <lpage>
       388
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021tktf.book.....A
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXjtVSqt7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       33575430
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.omtm.2020.12.008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR59">
     <label>
      59.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Livak
        </surname>
        <given-names>
         KJ
        </given-names>
       </name>
       <name>
        <surname>
         Schmittgen
        </surname>
        <given-names>
         TD
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
      </article-title>
      <source>
       Methods
      </source>
      <year>
       2001
      </year>
      <volume>
       25
      </volume>
      <fpage>
       402
      </fpage>
      <lpage>
       408
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38XhtFelt7s%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       11846609
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1006/meth.2001.1262
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR60">
     <label>
      60.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Riedel
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       An extended ΔCT-method facilitating normalisation with multiple reference genes suited for quantitative RT-PCR analyses of human hepatocyte-like cells
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2014
      </year>
      <volume>
       9
      </volume>
      <fpage>
       e93031
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2014PLoSO...993031R
      </pub-id>
      <pub-id pub-id-type="pmid">
       24658132
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3962476
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0093031
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR61">
     <label>
      61.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Campbell
        </surname>
        <given-names>
         KR
        </given-names>
       </name>
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <name>
        <surname>
         Wills
        </surname>
        <given-names>
         QF
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2017
      </year>
      <volume>
       33
      </volume>
      <fpage>
       1179
      </fpage>
      <lpage>
       1186
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXhvFagtL%2FP
      </pub-id>
      <pub-id pub-id-type="pmid">
       28088763
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5408845
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btw777
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR62">
     <label>
      62.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ilicic
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Classification of low quality cells from single-cell RNA-seq data
      </article-title>
      <source>
       Genome Biol.
      </source>
      <year>
       2016
      </year>
      <volume>
       17
      </volume>
      <pub-id pub-id-type="pmid">
       26887813
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4758103
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s13059-016-0888-1
      </pub-id>
      <elocation-id>
       29
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR63">
     <label>
      63.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         AITCHISON
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         HO
        </surname>
        <given-names>
         CH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The multivariate Poisson-log normal distribution
      </article-title>
      <source>
       Biometrika
      </source>
      <year>
       1989
      </year>
      <volume>
       76
      </volume>
      <fpage>
       643
      </fpage>
      <lpage>
       653
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       1041409
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/biomet/76.4.643
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR64">
     <label>
      64.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Robinson
        </surname>
        <given-names>
         MD
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Smyth
        </surname>
        <given-names>
         GK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2010
      </year>
      <volume>
       26
      </volume>
      <fpage>
       139
      </fpage>
      <lpage>
       140
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXhs1WlurvO
      </pub-id>
      <pub-id pub-id-type="pmid">
       19910308
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btp616
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR65">
     <label>
      65.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ritchie
        </surname>
        <given-names>
         ME
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       limma powers differential expression analyses for RNA-sequencing and microarray studies
      </article-title>
      <source>
       Nucleic Acids Res.
      </source>
      <year>
       2015
      </year>
      <volume>
       43
      </volume>
      <fpage>
       e47
      </fpage>
      <pub-id pub-id-type="pmid">
       25605792
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4402510
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/nar/gkv007
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR66">
     <label>
      66.
     </label>
     <mixed-citation publication-type="other">
      Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
      <italic>
       Stat. Appl. Genet. Mol. Biol.
      </italic>
      <bold>
       3
      </bold>
      , 3 (2004).
     </mixed-citation>
    </ref>
    <ref id="CR67">
     <label>
      67.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Phipson
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Lee
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Majewski
        </surname>
        <given-names>
         IJ
        </given-names>
       </name>
       <name>
        <surname>
         Alexander
        </surname>
        <given-names>
         WS
        </given-names>
       </name>
       <name>
        <surname>
         Smyth
        </surname>
        <given-names>
         GK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression
      </article-title>
      <source>
       Ann. Appl Stat.
      </source>
      <year>
       2016
      </year>
      <volume>
       10
      </volume>
      <fpage>
       946
      </fpage>
      <lpage>
       963
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       3528367
      </pub-id>
      <pub-id pub-id-type="pmid">
       28367255
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5373812
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1214/16-AOAS920
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR68">
     <label>
      68.
     </label>
     <mixed-citation publication-type="other">
      Wickham, H.
      <italic>
       Ggplot2
      </italic>
      (Springer International Publishing, 2016).
      <ext-link ext-link-type="doi" xlink:href="10.1007/978-3-319-24277-4">
       https://doi.org/10.1007/978-3-319-24277-4
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR69">
     <label>
      69.
     </label>
     <mixed-citation publication-type="other">
      The igraph software package for complex network research|BibSonomy.
      <ext-link ext-link-type="uri" xlink:href="https://www.bibsonomy.org/bibtex/bb49a4a77b42229a427fec316e9fe515">
       https://www.bibsonomy.org/bibtex/bb49a4a77b42229a427fec316e9fe515
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR70">
     <label>
      70.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Blondel
        </surname>
        <given-names>
         VD
        </given-names>
       </name>
       <name>
        <surname>
         Guillaume
        </surname>
        <given-names>
         J-L
        </given-names>
       </name>
       <name>
        <surname>
         Lambiotte
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Lefebvre
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Fast unfolding of communities in large networks
      </article-title>
      <source>
       J. Stat. Mech.
      </source>
      <year>
       2008
      </year>
      <volume>
       2008
      </volume>
      <fpage>
       P10008
      </fpage>
      <pub-id pub-id-type="doi">
       10.1088/1742-5468/2008/10/P10008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR71">
     <label>
      71.
     </label>
     <mixed-citation publication-type="other">
      Raivo Kolde. pheatmap: Pretty Heatmaps. 1.0.12
      <ext-link ext-link-type="doi" xlink:href="10.32614/CRAN.package.pheatmap">
       https://doi.org/10.32614/CRAN.package.pheatmap
      </ext-link>
      (2010).
     </mixed-citation>
    </ref>
    <ref id="CR72">
     <label>
      72.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lun
        </surname>
        <given-names>
         ATL
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <name>
        <surname>
         Marioni
        </surname>
        <given-names>
         JC
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor
      </article-title>
      <source>
       F1000Res
      </source>
      <year>
       2016
      </year>
      <volume>
       5
      </volume>
      <fpage>
       2122
      </fpage>
      <pub-id pub-id-type="pmid">
       27909575
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5112579
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR73">
     <label>
      73.
     </label>
     <mixed-citation publication-type="other">
      van der Maaten, L. &amp; Hinton, G. Visualizing Data using t-SNE.
      <italic>
       J. Mach. Learn. Res.
      </italic>
      <bold>
       9
      </bold>
      , 2579–2605 (2008).
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec41">
     <title>
      Taarifa ya ziada
     </title>
     <p id="Par61">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM4_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 1
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM5_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 2
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM6_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 3
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM7" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM7_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 4
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM8" xlink:title="Supplementary information">
       <media mime-subtype="quicktime" mimetype="video" xlink:href="MediaObjects/41467_2024_52388_MOESM8_ESM.mov">
        <caption xml:lang="en">
         <p>
          Supplementary Movie 5
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM9" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM9_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec42">
     <title>
      Data ya chanzo
     </title>
     <p id="Par62">
      <supplementary-material content-type="local-data" id="MOESM10" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52388_MOESM10_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Taarifa ya ziada
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-52388-1">
     https://doi.org/10.1038/s41467-024-52388-1
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
